




PCT/IB 0 4 / 0 1 0 7 5.

(2 5 . 0 3 . 0 4)



INVESTOR IN PEOPLE



The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears a correction, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew*

Dated 18 March 2004

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



31HAR03 E798270-1 D02093
P01/7700 0:00-0307268.3

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

PPD 70183/GB/P

2. Patent application number

(The Patent Office will fill in this part)

0307268.3

28 MAR 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames)

~~SYNGENTA Limited~~
~~European Regional Centre~~
~~Priestley Road~~
~~Surrey Research Park, Guildford,~~
~~Surrey, GU2 7YH, United Kingdom~~

SYNGENTA PARTICIPATIONS AG
SCHWARZWALDALLEE 215
CH - 4058 BASEL
SWITZERLAND

Patents ADP number (if you know it)

08290835001

~~6254007002~~

If the applicant is a corporate body, give the country/state of its incorporation

~~UNITED KINGDOM~~

SWITZERLAND

4. Title of the invention

ORGANIC COMPOUNDS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

John Richard WATERMAN
Intellectual Property Department
Syngenta Limited
Jealott's Hill International Research Centre
PO Box 3538
Bracknell, Berkshire, RG42 6YA
UNITED KINGDOM

Patents ADP number (if you know it)

8148298001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

YES (b)

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 45

Description

04

Claim(s)

Abstract 01

Drawing(s) 00

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.
Syngenta Limited

Signature M A Rudd
Authorised Signatory

Date 28 MARCH 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Margaret Ann RUDD - 01344 413673

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.


ORGANIC COMPOUNDS

The present invention relates to novel N-phenyl-[(4-pyridyl)-azinyl]-amine derivatives, to a method of protecting plants against attack or infestation by phytopathogenic organisms, such as nematodes or insects or especially microorganisms, preferably fungi, bacteria and viruses, or combinations of two or more of these organisms, by applying a N-phenyl-[(4-pyridyl)-azinyl]-amine derivative as specified hereinafter to a part and/or to the site of a plant, to the use of said derivative for protecting plants against said organisms, and to compositions comprising said derivative as the active component. The invention further relates to the preparation of these novel N-phenyl-[(4-pyridyl)-azinyl]-amine derivatives.

Certain N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives are disclosed in WO 01/93682 and WO 02/053560, as plant protection agents.

It has now been found that the new N-phenyl-[(4-pyridyl)-azinyl]-amines are effective in plant protection and related areas, showing advantageous properties in the treatment of plant diseases caused by organisms.

The novel N-phenyl-[(4-pyridyl)-azinyl]-amine derivatives according to the invention are those of the formula I



wherein

A and A' are both N or A and A' are both CH or A is CH and A' is N;

j is 0 or 1

R₁ is

- a) hydrazino, that is unsubstituted or one- to threefold substituted by optionally substituted alkyl and/or optionally substituted acyl,
- b) cyclohexylamino, tetrahydro-4H-pyran-4-amino, pyrrolidine-3-amino, 2- or 3-

tetrahydro- furylamino, all optionally substituted by amino, hydroxy, alkoxy, alkyl or alkoxyalkyl,

c) piperazinyl that is optionally substituted by amino, amino-lower alkyl, hydroxy, alkoxy, alkyl or alkoxyalkyl,

5 d) morpholinyl that is optionally substituted by amino, amino-lower alkyl, hydroxy, alkoxy, alkyl or alkoxyalkyl,

e) amino or mono- or di-(lower alkyl)amino wherein the lower alkyl moieties are unsubstituted or substituted by one or more (preferably 1 to 3, especially 1 or 2) substituents independently selected from the group consisting of unsubstituted amino, N-

10 mono- or N,N-di-(lower alkyl)-amino, (lower alkoxy)-lower alk-oxy, lower alkoxy-carbonylamino, hydroxy-lower alkoxy-carbonylamino, lower alkoxy-lower alkoxy-carbonylamino, morpholinyl, hydroxy-lower alkylamino, cyano, halogen, oxo, hydroximino, alkoximino, optionally substituted hydrazono, lower alkenyl, lower alkynyl, guanidyl, lower alkanoylamino, hydroxy-lower alkanoylamino, lower alkoxy-

15 lower alkanoylamino, halo-lower alkanoylamino, lower alkylaminocarbonylamino, hydroxy-lower alkylaminocarbonylamino, lower alkoxy-lower alkylaminocarbonylamino, amidino, di-lower-alkylamino-cyclohexyl, carboxy, lower alkoxy-carbonyl, hydroxy-lower alkoxy-carbonyl, lower alkoxy-lower alkoxy-carbonyl, lower alkylcarbonyldioxy (= lower alkoxy-carbonyloxy), hydroxy-lower

20 alkoxy-carbonyloxy, lower alkoxy-lower alkoxy-carbonyloxy, lower alkanoyloxy, halo-lower alkanoyloxy, hydroxy-lower alkanoyloxy, lower alkoxy-lower alkanoyloxy, carbamoyl, N-mono- or N,N-di-lower alkylcarbamoyl, N-(hydroxy-lower alkyl)carbamoyl, N-lower alkyl-N-hydroxy-lower alkyl-carbamoyl, N,N-di-(hydroxy-lower alkyl)-carbamoyl, N-hydroxy-carbamoyl, hydroxy, lower alkoxy, lower

25 alkenyloxy, lower alkinyloxy, lower haloalkoxy, lower alkylthio, lower alkylsulfoxyl, lower alkylsulfonyl, lower alkoxysilyl, 4-tetrahydro-4H-pyranyl, 3-pyrrolidinyl, 2- or 3-tetrahydrofuryl, 2- or 3-dihydrofuryl, piperazinyl, lower alkanoyl-piperazinyl (including formylpiperazinyl), optionally substituted heteroaryl and optionally substituted heteroaryloxy,

30 f) optionally substituted alkanoylamino, optionally substituted alkenoylamino, optionally substituted alkynoylamino, optionally substituted mono- or di-alkylaminocarbonylamino, optionally substituted alkoxy-carbonylamino, optionally substituted mono- or di-alkylaminosulfonylamino, optionally substituted mono- or di-alkylaminosulfoxylamino,

- g) N-(optionally substituted alkyl)-N-(optionally substituted lower alkanoyl)-amino, .
 h) N-(optionally substituted alkyl)-N-(optionally substituted alkoxy-carbonyl)-amino,
 i) N-(optionally substituted alkyl)-N-(N',N'-mono- or di-[optionally substituted alkyl]-aminocarbonyl)-amino,
 5 j) $N=C(R_7, R_8)$ wherein R_7 is hydrogen, alkyl, amino, mono- or di-alkylamino and R_8 is amino, mono- or dialkylamino or wherein R_7 and R_8 , together with the binding carbon atom, form a saturated five- to seven-membered ring with 0, 1 or 2 ring nitrogen atoms that is optionally substituted by one or more substituents, preferably 1 to 3 substituents, especially lower alkyl,
 10 k) an optionally substituted 4 to 7 membered heterocyclyl group containing one or two nitrogen, oxygen or sulfur atoms but at least one nitrogen atom through which the heterocyclyl ring is attached to the remainder of the molecule;
 R_2 is hydrogen, C_1 - C_4 -alkyl, C_3 - C_4 -alkenyl, C_3 - C_4 -alkynyl, $-CH_2OR_{16}$, $-CH_2SR_{16}$, $-C(O)R_{16}$, $-C(O)OR_{16}$, SO_2R_{16} , SOR_{16} or SR_{16}
 15 where R_{16} is C_1 - C_8 -alkyl, C_1 - C_8 -alkoxyalkyl, C_1 - C_8 haloalkyl or phenyl- C_1 - C_2 -alkyl, wherein the phenyl may be substituted by up to three groups selected from halo or C_1 - C_4 -alkyl;
 R_3 is hydrogen, halogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 haloalkoxy; hydroxy, mercapto, cyano or C_1 - C_4 alkoxy;
 20 R_4 , R_5 and R_6 are independently of each other hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted acyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted acylamino, optionally substituted thioalkyl, $COOR_{17}$, $CONR_{18}R_{19}$, $S(O)_kR_{20}$, $SO_2NR_{21}R_{22}$, $NR_{23}R_{24}$, $NR_{25}SO_2R_{26}$, NO_2 , CN ,
 25 $C(=O)R_{27}$, $C(=NOR_{28})R_{29}$ or R_4 and R_5 or R_5 and R_6 together form a five to six – membered saturated or unsaturated carbocyclic ring system or ring system or a five to six – membered heteroaromatic or heterocyclic ring system which is optionally substituted and contains one to three heteroatoms selected from O, N or S;
 k is 0, 1 or 2 and
 30 R_{17} , R_{18} , R_{19} , R_{20} , R_{21} , R_{22} , R_{23} , R_{24} , R_{25} , R_{26} , R_{27} , R_{28} and R_{29} are independently H or optionally substituted alkyl or optionally substituted aryl; or a salt thereof
 provided that when A is CH, A' is N and R_3 , R_5 and R_6 are all H then R_4 is not hydrogen, halogen, alkoxy, haloalkyl, haloalkoxy or alkyl.

In the context of the present specification alkyl as a group *per se* and as a structural element of hydroxyalkyl, thioalkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, alkynyloxy or haloalkoxy - is preferably C₁-C₆-alkyl, more preferably lower alkyl, and is linear i.e. methyl, ethyl, propyl, butyl, pentyl or hexyl, or branched, e.g. isopropyl, isobutyl, sec.-butyl, tert.-butyl, isopentyl, neopentyl or isohexyl. Lower alkyl is preferably methyl or ethyl.

Specific examples of alkenyl and alkynyl include allyl, 2-butenyl, 3-butenyl, propargyl, 2-butyne and 3 butyne.

When present, the optional substituents on an alkyl, alkenyl or alkynyl moiety include one or more of halogen, nitro, cyano, oxo (and acetals and ketals formed therefrom), C₃₋₇ cycloalkyl (itself optionally substituted with C₁₋₆ alkyl or halogen), C₅₋₇ cycloalkenyl (itself optionally substituted with C₁₋₆ alkyl or halogen), hydroxy, C₃₋₁₀ alkoxy, C₃₋₁₀ alkoxy(C₃₋₁₀)alkoxy, C₁₋₆ alkoxy-carbonyl(C₃₋₁₀)alkoxy, C₃₋₁₀ haloalkoxy, phenyl(C₁₋₄)alkoxy (where the phenyl group is optionally substituted by one or more of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, CN, nitro or halogen), C₃₋₇ cycloalkyloxy (where the cycloalkyl group is optionally substituted with C₁₋₆ alkyl or halogen), C₃₋₁₀ alkenyloxy, C₃₋₁₀ alkynyloxy, SH, C₃₋₁₀ alkylthio, C₃₋₁₀ haloalkylthio, phenyl(C₁₋₄)-alkylthio (where the phenyl group is optionally substituted by one or more of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, CN, nitro or halogen), C₃₋₇ cycloalkylthio (where the cycloalkyl group is optionally substituted with C₁₋₆ alkyl or halogen), tri(C₁₋₄)-alkylsilyl(C₁₋₆)alkylthio, phenylthio (where the phenyl group is optionally substituted by one or more of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, CN, nitro or halogen), C₁₋₆ alkylsulfonyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ haloalkylsulfinyl, phenylsulfonyl (where the phenyl group is optionally substituted by one or more of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, CN, nitro or halogen), tri(C₁₋₄)alkylsilyl, phenyldi-(C₁₋₄)alkylsilyl, (C₁₋₄)alkyldiarylsilyl, triphenylsilyl, C₃₋₁₀ alkylcarbonyl, HO₂C, C₃₋₁₀ alkoxy carbonyl, aminocarbonyl, C₁₋₆ alkylaminocarbonyl, di(C₁₋₆ alkyl)-aminocarbonyl, N-(C₁₋₃ alkyl)-N-(C₁₋₃ alkoxy)aminocarbonyl, C₁₋₆ alkylcarbonyloxy, phenylcarbonyloxy (where the phenyl group is optionally substituted by one or more of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, CN, nitro or halogen), di(C₁₋₆)alkylaminocarbonyloxy, phenyl (itself optionally substituted by one or more of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, CN, nitro or halogen), naphthyl (itself optionally substituted by C₁₋₆ alkyl or halogen), heteroaryl (itself optionally substituted by C₁₋₆ alkyl or halogen), heterocyclyl (itself

optionally substituted with C₁₋₆ alkyl or halogen), phenoxy (where the phenyl group is optionally substituted by substituted by one or more of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, CN, nitro or halogen), naphthoxy (where the naphthyl group is optionally substituted by C₁₋₆ alkyl or halogen), heteroaryloxy, (where the heteroaryl group is optionally substituted by C₁₋₆ alkyl or halogen), heterocycloxy (where the heterocycl group is optionally substituted with C₁₋₆ alkyl or halogen), amino, C₁₋₆ alkylamino, di-(C₁₋₆) alkylamino, C₁₋₆ alkylcarbonylamino and N-(C₁₋₆)alkylcarbonyl-N-(C₁₋₆)-alkylamino.

Preferred substituents on an alkyl, alkenyl or alkynyl moiety include one or more of halogen, nitro, cyano, C₃₋₇ cycloalkyl (itself optionally substituted with C₁₋₆ alkyl or halogen), C₅₋₇ cycloalkenyl (itself optionally substituted with C₁₋₆ alkyl or halogen), hydroxy, C₃₋₁₀ alkoxy, C₃₋₁₀ alkoxy(C₃₋₁₀)alkoxy, C₁₋₆ alkoxy-carbonyl(C₃₋₁₀)alkoxy, C₃₋₁₀ haloalkoxy, phenyl(C₁₋₄)alkoxy (where the phenyl group is optionally substituted by C₁₋₆ alkyl or halogen), C₃₋₇ cycloalkyloxy (where the cycloalkyl group is optionally substituted with C₁₋₆ alkyl or halogen), C₃₋₁₀ alkenyloxy, C₃₋₁₀ alkynyloxy, SH, C₃₋₁₀ alkylthio, C₃₋₁₀ haloalkylthio, phenyl(C₁₋₄)alkylthio (where the phenyl group is optionally substituted by C₁₋₆ alkyl or halogen), C₃₋₇ cycloalkylthio (where the cycloalkyl group is optionally substituted with C₁₋₆ alkyl or halogen), tri(C₁₋₄)alkylsilyl(C₁₋₆)alkylthio, phenylthio (where the phenyl group is optionally substituted by C₁₋₆ alkyl or halogen), C₁₋₆ alkylsulfonyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ haloalkylsulfinyl, phenylsulfonyl (where the phenyl group is optionally substituted by C₁₋₆ alkyl or halogen), tri(C₁₋₄)alkylsilyl, phenyldi(C₁₋₄)alkylsilyl, (C₁₋₄)alkyldiarylsilyl, triphenylsilyl, C₃₋₁₀ alkylcarbonyl, HO₂C, C₃₋₁₀ alkoxycarbonyl, aminocarbonyl, C₁₋₆ alkylaminocarbonyl, di(C₁₋₆ alkyl)-aminocarbonyl, N-(C₁₋₃ alkyl)-N-(C₁₋₃ alkoxy)aminocarbonyl, C₁₋₆ alkylcarbonyloxy, phenylcarbonyloxy (where the phenyl group is optionally substituted by C₁₋₆ alkyl or halogen), di(C₁₋₆)alkylaminocarbonyloxy, phenyl (itself optionally substituted by C₁₋₆ alkyl or halogen), heteroaryl (itself optionally substituted by C₁₋₆ alkyl or halogen), heterocyclyl (itself optionally substituted with C₁₋₆ alkyl or halogen), phenoxy (where the phenyl group is optionally substituted by C₁₋₆ alkyl or halogen), heteroaryloxy, (where the heteroaryl group is optionally substituted by C₁₋₆ alkyl or halogen), heterocycloxy (where the heterocycl group is optionally substituted with C₁₋₆ alkyl or halogen), amino, C₁₋₆ alkylamino, di(C₁₋₆) alkylamino, C₁₋₆ alkylcarbonylamino and N-(C₁₋₆)alkylcarbonyl-N-(C₁₋₆)alkylamino.

More preferred substituents on an alkyl, alkenyl and alkynyl moiety include one or more of halogen, nitro, cyano, C₃₋₇ cycloalkyl (itself optionally substituted with C₁₋₆ alkyl or halogen), hydroxy, C₃₋₁₀ alkoxy, C₃₋₁₀ alkoxy(C₃₋₁₀)alkoxy, C₁₋₆ alkoxy-carbonyl(C₃₋₁₀)alkoxy, C₃₋₁₀ haloalkoxy, SH, C₃₋₁₀ alkylthio, C₃₋₁₀ haloalkylthio, C₁₋₆ alkylsulfonyl, C₁₋₆ haloalkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ haloalkylsulfinyl, phenylsulfonyl (where the phenyl group is optionally substituted by C₁₋₆ alkyl or halogen), HO₂C, C₃₋₁₀ alkoxy-carbonyl, aminocarbonyl, C₁₋₆ alkylaminocarbonyl, heteroaryl (itself optionally substituted by C₁₋₆ alkyl or halogen), heterocyclyl (itself optionally substituted with C₁₋₆ alkyl or halogen), phenyloxy (where the phenyl group is optionally substituted by C₁₋₆ alkyl or halogen), amino, C₁₋₆ alkylamino and di(C₁₋₆) alkylamino.

Aryl includes naphthyl, anthracyl, fluorenyl and indenyl but is preferably phenyl.

The term heteroaryl and heteroaromatic refer to an aromatic ring containing up to 10 atoms including one or more heteroatoms (preferably one or two heteroatoms) selected from O, S and N. Examples of such rings include benzimidazolyl, benzisoxazolyl, benzisothiazolyl, benzocoumarinyl, benzofuryl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzoxazolyl, benzoxdiazolyl, quinazolinyl, quinolyl, quinoxalinyl, carbazolyl, dihydrobenzofuryl, furyl (especially 2- or 3-furyl), imidazolyl (especially 1-imidazolyl), indazolyl, indolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, naphthyridinyl, oxazolyl, phenanthridinyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrazolo[3,4-b]-pyridyl, pyridyl (especially 2-, 3- or 4-pyridyl), pyrimidyl, pyrrolyl, tetrazolyl (especially tetrazol-1-yl), oxadiazolyl, thiadiazolyl, thiazolyl (especially 2-, 4- or 5-thiazolyl), thienyl (especially 2- or 3-thienyl), triazinyl (especially 1,3,5-triazinyl) and triazolyl (especially 1,2,4-triazol-1-yl). Pyridine, pyrimidine, furan, quinoline, quinazoline, pyrazole, thiophene, thiazole, oxazole and isoxazole are preferred.

The terms heterocycle and heterocyclyl refer to a non-aromatic ring containing up to 10 atoms including one or more (preferably one or two) heteroatoms selected from O, S and N. Examples of such rings include 1,3-dioxolane, tetrahydrofuran and morpholine.

When present, the optional substituents on heterocyclyl include C₁₋₆ alkyl as well as those optional substituents given above for an alkyl moiety.

Carbocyclic rings include aryl, cycloalkyl and cycloalkenyl rings.

Cycloalkyl includes cyclopropyl, cyclopentyl and cyclohexyl.

Cycloalkenyl includes cyclopentenyl and cyclohexenyl.

When present, the optional substituents on heteroaryl and aryl rings are selected, independently, from halogen, nitro, cyano, NCS-, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy-(C₁₋₆)alkyl, C₂₋₆ alkenyl, C₂₋₆ haloalkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl (itself optionally substituted with C₁₋₆ alkyl or halogen), C₅₋₇ cycloalkenyl (itself optionally substituted with C₁₋₆ alkyl or halogen), hydroxy, C₁₋₁₀ alkoxy, C₁₋₁₀ alkoxy(C₁₋₁₀)alkoxy, tri(C₁₋₄)alkyl-silyl(C₁₋₆)alkoxy, C₁₋₆ alkoxycarbonyl(C₁₋₁₀)alkoxy, C₁₋₁₀ haloalkoxy, aryl(C₁₋₄)alkoxy (where the aryl group is optionally substituted), C₃₋₇ cycloalkyloxy (where the cycloalkyl group is optionally substituted with C₁₋₆ alkyl or halogen), C₁₋₁₀ alkenyloxy, C₁₋₁₀ alkynyloxy, SH, C₁₋₁₀ alkylthio, C₁₋₁₀ haloalkylthio, aryl(C₁₋₄)alkylthio (where the aryl group may be further optionally substituted), C₃₋₇ cycloalkylthio (where the cycloalkyl group is optionally substituted with C₁₋₆ alkyl or halogen), tri(C₁₋₄)-alkylsilyl(C₁₋₆)alkylthio, arylthio (where the aryl group is optionally substituted), C₁₋₆ alkylsulfonfyl, C₁₋₆ haloalkylsulfonfyl, C₁₋₆ alkylsulfynyl, C₁₋₆ haloalkylsulfynyl, arylsulfonfyl (where the aryl group is optionally substituted), tri(C₁₋₄)alkylsilyl, aryl-di-(C₁₋₄)alkylsilyl, (C₁₋₄)alkyldiarylsilyl, triarylsilyl, C₁₋₁₀ alkylcarbonyl, HO₂C, C₁₋₁₀ alkoxycarbonyl, aminocarbonyl, C₁₋₆ alkylaminocarbonyl, di(C₁₋₆ alkyl)aminocarbonyl, N-(C₁₋₃ alkyl)-N-(C₁₋₃ alkoxy)aminocarbonyl, C₁₋₆ alkylcarbonyloxy, arylcarbonyloxy (where the aryl group is optionally substituted), di(C₁₋₆)alkylamino-carbonyloxy, aryl (itself optionally substituted), heteroaryl (which itself may be further optionally substituted), heterocyclyl (itself optionally substituted with C₁₋₆ alkyl or halogen), aryloxy (where the aryl group is optionally substituted), heteroaryloxy (where the heteroaryl group is optionally substituted), heterocycliloxy (where the heterocyclyl group is optionally substituted with C₁₋₆ alkyl or halogen), amino, C₁₋₆ alkylamino, di-(C₁₋₆)alkylamino, C₁₋₆ alkylcarbonylamino and N-(C₁₋₆)alkylcarbonyl-N-(C₁₋₆)-alkylamino.

For substituted phenyl and heteroaryl moieties it is preferred that one or more substituents are independently selected from halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ alkylthio, C₁₋₆ haloalkylthio, C₁₋₆ alkylsulfynyl, C₁₋₆ haloalkylsulfynyl, C₁₋₆ alkylsulfonfyl, C₁₋₆ haloalkylsulfonfyl, C₂₋₆ alkenyl, C₂₋₆ haloalkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, nitro, cyano, CO₂H, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxycarbonyl, R₃₃R₃₄N or R₃₅R₃₆NC(O); wherein R₃₃, R₃₄, R₃₅ and R₃₆ are, independently, hydrogen or C₁₋₆ alkyl.

In the context of the specification the term halogen is fluorine, bromine, iodine or preferably chlorine; similarly haloalkyl is preferably C₁-C₆-alkyl, more preferably lower alkyl, that is linear or branched and is substituted by one or more, for example in the case of halo-ethyl up to five, halogen atoms, especially fluorine (an example is trifluoromethyl).

Haloalkoxy is preferably C₁-C₆-alkoxy, more preferably lower alkoxy, that is linear or branched and that is substituted by one or more, for example in the case of halo-ethyl up to five, halogen atoms, especially fluorine; trifluoromethoxy and 1,1,2,2-tetrafluoroethoxy are especially preferred.

Acyl is preferably C₁-C₁₆ alkanoyl, more preferably lower alkanoyl, and is linear or branched. Lower alkanoyl is preferably formyl, acetyl or in a broader sense of the invention propionyl or butyryl.

The compounds of formula I can form acid addition salts, for example with inorganic acids, such as hydrochloric acid, sulfuric acid or a phosphoric acid, or with suitable organic carboxylic or sulfonic acids, for example aliphatic mono- or dicarboxylic acids, such as trifluoroacetic acid, acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, fumaric acid, hydroxymaleic acid, malic acid, tartaric acid, citric acid, oxalic acid or amino acids, such as arginine or lysine, aromatic carboxylic acids, such as benzoic acid, 2-phenoxy-benzoic acid, 2-acetoxy-benzoic acid, salicylic acid, 4-aminosalicylic acid, aromatic-aliphatic carboxylic acids, such as mandelic acid or cinnamic acid, heteroaromatic carboxylic acids, such as nicotinic acid or isonicotinic acid, aliphatic sulfonic acids, such as methane-, ethane- or 2-hydroxy-ethane-sulfonic acid, or aromatic sulfonic acids, for example benzene-, p-toluene- or naphthalene-2-sulfonic acid.

The pyridine-N-oxides of formula I can form acid addition salts with strong acids, such as hydrochloric acid, nitric acid, phosphoric acid or sulfonic acids, such as benzenesulfonic acid.

Formula I according to the invention shall include all the possible isomeric forms, as well as mixtures, e.g. racemic mixtures, and any mixtures of rotamers.

In view of the close relationship between the compounds of formula I in free form and in the form of their salts, including also salts that can be used as intermediates, for example in the purification of the compounds of formula I or in order to identify those compounds, herein-before and hereinafter any reference to the (free) compounds is to be

understood as including also the corresponding salts, where appropriate and expedient.

Among the compounds of formula I according to the present invention the following groups of compounds are preferred. These groups are in any combination those wherein

5 j is 0;

R₁ is hydrazino substituted by one to three substituents independently selected from the group consisting of C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄ alkoxyC₁₋₄ alkyl and C₁₋₄ acyl; or

R₁ is cyclohexyl-amino substituted by amino; or

10 R₁ is piperazinyl optionally substituted by one or two C₁₋₄ alkyl, acyl or C₁₋₄ aminoalkyl groups; or


R₁ is morpholinyl optionally substituted by one or two C₁₋₄ alkyl, acyl or C₁₋₄ aminoalkyl groups; mono- or di-(lower alkyl)-amino; or

15 R₁ is mono- or di-(lower alkyl)-amino where the lower alkyl moieties are independently substituted by N-mono- or N,N-di-(lower alkyl)amino, (lower alkoxy)-lower alkoxy, caboxy-lower alkyl, lower alkoxy, hydroxy, hydroxy-lower alkylamino, lower alkylamino-carbonylamino or lower alkoxy-carbonylamino; or

R₁ is C₁₋₈ alkoximino; or

20 R₁ is N=CR₇R₈ where R₇ and R₈ together with the carbon atom to which they are attached form a five- to seven-membered ring with 2 ring nitrogen atoms adjacent to the carbon atom double bonded to the external N atom; or

R₁ is the moiety



wherein

25 the sum of (m + p) together is 0, 1, 2 or 3;

q is 0 or 1, and the sum of (m + p + q) together is 1, 2, 3 or 4;

R₉ is hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl or C₁-C₆-alkoxy;

R₁₀ is hydrogen, C₁-C₆-alkyl, C₃-C₄-alkenyl or C₃-C₄-alkynyl;

each of R₁₁, R₁₂, R₁₃ and R₁₄ is, independently of the others, hydrogen, C₁-C₆-alkyl,

30 C₁-C₆-haloalkyl, hydroxy-C₁-C₆-alkyl or C₁-C₆-alkoxy-C₁-C₆-alkyl, or the ring members

- CR₁₃R₁₄ or CR₁₁R₁₂ or CR₉R₁₀ are independently of each other a carbonyl group (C=O) or a group C=S;
- X is C=O, C=S, S=O or O=S=O;
- Y is O, S, C=O, CH₂, -N(R₁₅)-, -O-N(R₁₅)-, -N(R₁₅)-O- or -NH-; and
- 5 R₁₅ is C₁-C₈-alkyl, C₁-C₈-alkoxyalkyl, C₁-C₈ haloalkyl or phenylC₁-C₂-alkyl wherein the phenyl may be substituted by up to three groups selected from halo or C₁-C₄-alkyl; or
- R₁ is hydrazino substituted by a lower alkyl, trifluoromethyl, 2-hydroxyethyl, hydroxymethyl, 1-hydroxymethyl-n-propyl, 2-methoxyethyl, ethoxymethyl, or 1-methoxymethyl-n-propyl group and especially by 2-hydroxyethyl group; or
- 10 R₁ is 2- or 4-amino-cyclohexyl-amino; or
- R₁ is 4-(2-amino-ethyl)-piperazin-1-yl; or
- R₁ is 4-formyl-piperazinyl; or
- R₁ is 4-morpholinyl; or
- R₁ is 2-morpholin-4-yl-ethylamino, 3-lower alkyl- or 3,5-di(lower alkyl)morpholino, especially 3-methyl- or 3,5-dimethylmorpholino; or
- 15 R₁ is dimethylamino, 3-(dimethylamino)-1-methyl-n-propylamino, 2-amino-ethylamino, 3-amino-n-propylamino, N-(methoxymethyl)-N-{2-[(methoxy)-methoxy]-1-methyl-ethyl}-amino, 2-hydroxy-ethylamino, 3-(2-hydroxy-ethyl-amino)-prop-1-ylamino, methylamino-carbonyl-amino, 2- or 3-hydroxy-n-propylamino, 1,1-dimethyl-3-hydroxy-n-propylamino, 1-n-propyl-2-hydroxy-ethylamino, 1,1-dimethyl-2-hydroxy-ethylamino,
- 20 1-ethyl-2-hydroxy-ethylamino, 2-hydroxy-1-(hydroxymethyl)-ethylamino, 2-hydroxy-1-methyl-ethylamino, 2-hydroxy-1-(sec-butyl)-ethylamino, 2-methoxy-ethylamino, 1-ethyl-2-methoxy-ethylamino, 2-methoxy-1-methyl-ethylamino, 2-methoxy-2-methyl-ethylamino, 1,1-dimethyl-2-methoxy-ethylamino, 1,1-dimethyl-3-methoxy-n-propyl-amino, 3-methoxy-propylamino or 3-[N-(ethoxycarbonyl)-amino]-n-propylamino; or
- 25 R₁ is an imidazolidin-2-ylidene, tetrahydropyrimidin-2-ylidene or hexahydro-1,3-diazepin-2-ylidene moiety which is optionally substituted, especially unsubstituted or substituted by one to three lower alkyl moieties, especially methyl, ethyl, propyl or isopropyl, which may be bound to carbon or nitrogen ring atoms; or
- 30 R₁ is N-oxazolidin-2-one, N-oxazolidin-2-thione, N-[1,2,3]oxathiazolidine-2-oxide, N-[1,2,3]oxathiazolidine-2,2-dioxide, N-pyrrolidin-2-one, N-pyrrolidin-2-thione, N-pyrrolidine-2,5-dione, N-thiazolidin-2-one, N-4-methylene-oxazolidin-2-one, N-piperidine-2,6-dione, N-morpholine-2,3-dione,

N-morpholine-2,5-dione, N-imidazolidin-2-one, N-[1,2,4]-oxazolidin-5-one, N-[1,2,4]-oxazolidin-3-one, N-[1,2,5]oxadiazinan-6-one, N-[1,2,4]oxadiazinan-3-one, azepan-2-one or [1,3]oxazinan-2-one; or

R₁ is N-oxazolidin-2-one, N-oxazolidin-2-thione, N-[1,2,3]oxathiazolidine-2-oxide and N-pyrrolidin-2-one;

R₂ is hydrogen, C₃-C₄-alkenyl, C₃-C₄-alkynyl, -CH₂OR₁₆, CH₂SR₁₆, -C(O)R₁₆, -C(O)OR₁₆, SOR₁₆ or SR₁₆; or

R₂ is hydrogen, -CH₂OR₁₆, CH₂SR₁₆ or SR₁₆; where R₁₆ is as defined above;

R₃ is H, OH, halogen, loweralkyl, lower alkoxy, CN or

10 R₃ is H, Cl, F, OH, CH₃ or OCH₃ or

R₃ is H or F or

R₃ is H;

R₄ is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted

15 alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkyl optionally substituted aryl, COOR₁₇, CONR₁₈R₁₉, S(O)_kR₂₀, SO₂NR₂₁R₂₂ or NR₂₃R₂₄ where

R₁₇, R₁₈, R₁₉, R₂₀, R₂₁, R₂₂, R₂₃ and R₂₄ are H or C₁₋₄ alkyl; or

R₄ is hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆cyanoalkyl, C₃-C₇cycloalkyl, C₂-C₆alkenyl, C₂-C₆haloalkenyl, C₂-C₆alkynyl, C₂-C₆haloalkynyl, amino, C₁-C₆alkylamino,

20 di(C₁-C₆alkyl)-amino, halogen, hydroxy, mercapto, cyano, C₁-C₆alkoxy, C₃-

C₆alkenyloxy, C₃-C₆alkynyloxy, C₁-C₆haloalkoxy, C₁-C₈alkanoyloxy-C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆alkylsulfinyl, C₁-C₆alkylsulfonyl, C₁-C₆hydroxyalkyl, (C₁-C₄alkoxy)_n-C₁-C₆alkyl, C₁-C₆aminoalkyl, C₁-C₄alkyl-C₁-C₆aminoalkyl, di(C₁-C₄alkyl)-

C₁-C₆aminoalkyl, C₁-C₈alkoxycarbonyl, C₁-C₈alkanoyl-C₁-C₆aminoalkyl, optionally

25 substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or

a group -CO-R₃₉, -O-CO-R₉, -NH-CO-R₃₉, -(C₁-C₆alkylene-)-CO-R₃₉,

-C₁-C₄(-O-C₁-C₆alkylene-O)_n-R₃₉, -C(=NO R₃₉)-R₄₀ or -CO-N R₃₉R₄₀;

where R₃₉, R₄₀, are independently H or optionally substituted alkyl;

R₅ is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl,

30 optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted

alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkyl optionally substituted aryl, COOR₄₁, CONR₄₂R₄₃, S(O)_qR₄₄, SO₂NR₄₅R₄₆ or NR_{45a}R_{46a} where R₄₁,

R₄₂, R₄₃, R₄₄, R₄₅, R₄₆, R_{45a}, R_{46a}, are independently H or optionally substituted alkyl or

R₅ is hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆cyanoalkyl, C₃-C₇cycloalkyl, C₂-C₆alkenyl, C₂-C₆haloalkenyl, C₂-C₆alkynyl, C₂-C₆haloalkynyl, amino, C₁-C₆alkylamino, di(C₁-C₆alkyl)-amino, halogen, hydroxy, mercapto, cyano, C₁-C₆alkoxy, C₃-C₆alkenyloxy, C₃-C₆alkynyloxy, C₁-C₆haloalkoxy, C₁-C₈alkanoyloxy-C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆alkylsulfinyl, C₁-C₆alkylsulfonyl, C₁-C₆hydroxyalkyl, (C₁-C₄alkoxy)_n-C₁-C₆alkyl, C₁-C₆aminoalkyl, C₁-C₄alkyl-C₁-C₆aminoalkyl, di(C₁-C₄alkyl)-C₁-C₆aminoalkyl, C₁-C₈alkoxycarbonyl, C₁-C₈alkanoyl-C₁-C₆aminoalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a group -CO-R₅₂, -O-CO-R₅₂, -NH-CO-R₅₂, -(C₁-C₆alkylene)-CO-R₅₂, -C₁-C₄(-O-C₁-C₆alkylene-O-)_n-R₄₇, -C(=NOR₄₈)-R₄₉ or -CO-NR₅₀R₅₁ where R₄₇, R₄₈, R₄₉, R₅₀, R₅₁ and R₅₂ are independently H or optionally substituted alkyl; R₆ is hydrogen, C₁-C₆alkyl or C₁-C₆haloalkyl; halogen, hydroxy, mercapto, cyano, C₁-C₆alkoxy, C₁-C₆alkylthio, amino, C₁-C₆alkylamino, di(C₁-C₆alkyl)-amino, -O-CO-R₅₄, -NH-CO-R₅₃, where R₅₃ and R₅₄, are independently H or optionally substituted alkyl.

15 Preferred individual compounds of the formula I are listed in the following


Tables:

Table A1(a): Compounds of formula I in which A and A' have the same value designated in the Table as "A" and j, R₁, R₂, R₃, R₄, R₅ and R₆ have the values shown.

| No. | A | R1 | R2 | R3 | R4 | R5 | R6 | j | mp/°C |
|-------|----|--|----|----|------------------|------------------|----|---|---------|
| A1.01 | N | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | CF ₃ | H | 0 | 193-194 |
| A1.02 | N | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | H | 0 | 147-148 |
| A1.03 | N | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | Cl | H | H | 0 | 158-159 |
| A1.04 | N | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Cl | H | 0 | 200-201 |
| A1.05 | N | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | CH ₃ | H | H | 0 | 168-169 |
| A1.06 | N | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | CH ₃ | H | 0 | 185-187 |
| A1.07 | N | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | CF ₃ | H | H | 0 | 192-193 |
| A1.08 | N | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | OCH ₃ | H | H | 0 | 124-125 |
| A1.09 | N | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | OCH ₃ | H | 0 | 159-160 |
| A1.10 | CH | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | Cl | H | H | 0 | 110 |
| A1.11 | CH | 4-methyl-oxazolidin-2-one | H | H | Cl | H | H | 0 | 220-221 |

Table A1(b): Compounds of formula I in which A is CH and A' is N and j, R₁, R₂, R₃, R₄, R₅ and R₆ have the values shown. For these compounds either mp are given or retention times (RT) (using a YMC CombiScreen ODS-AQ column; 30 x 4.6mm; 5um; solvent mixture: 89% H₂O + 11% CH₃CN (0.1TFA) at a flow rate of 3.5ml/min).

5

| No. | R ₁ | R ₂ | R ₃ | R ₄ | R ₅ | R ₆ | j | mp/°C RT |
|-------|---|----------------|----------------|----------------|----------------------------|------------------|---|-------------|
| A1.12 | 4-methyl-oxazolidin-2-one | H | H | Cl | OH | H | 0 | 178-80 |
| A1.13 | 4-methyl-oxazolidin-2-one | H | OH | Cl | H | H | 0 | 225-226 |
| A1.14 | 4-methyl-oxazolidin-2-one | H | OH | H | H | Cl | 0 | 213-215 |
| A1.15 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | OMe | Cl | 0 | 108-110 |
| A1.16 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Me | Cl | 0 | 145-146 |
| A1.17 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | Cl | H | Cl | 0 | 147-148 |
| A1.18 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | F | Cl | 0 | 139-141 |
| A1.19 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | F | H | F | 0 | 142-144 |
| A1.20 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | NO ₂ | 0 | 113-114 |
| A1.21 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | CO ₂ Me | H | 0 | 159-161 |
| A1.22 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | -NH-CH=CH- | | 0 | 82-85 |
| A1.23 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | -NH-N=CH- | | 0 | 165-169 |
| A1.24 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | -O-CF ₂ -O- | | 0 | 140-144 |
| A1.25 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | -CH=N-NH- | | 0 | 187-188 |
| A1.26 |  | H | H | H | -O-CF ₂ -O- | | 0 | 199-200 |
| A1.27 | NHCH(CH ₃)CH ₂ OH | H | F | Cl | H | H | 0 | 140-141 |
| A1.28 | NHCHCH ₂ OH | H | F | H | H | Cl | 0 | 156-157 |
| A1.29 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | SMe | 0 | 120-122 |
| A1.30 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | SCF ₃ | 0 | 133-134 |
| A1.31 | NHCH(CH ₃)CH ₂ OH | H | Me | Cl | H | H | 0 | 150 |
| A1.32 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | -CH=CH-S(O ₂)- | | 0 | resin |

| | | | | | | | | |
|-------|---|---|----|-----------------|------------------------|--------------------|---|----------|
| A1.33 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | -NH-C(Me)=CH- | | 0 | 98-101 |
| A1.34 | NHCH(CH ₃)CH ₂ OAc | H | H | H | H | -NHAc | 0 | 163 |
| A1.35 | NHCH ₂ CH ₂ CH ₂ OH | H | H | H | -O-CF ₂ -O- | | 0 | 189-192 |
| A1.36 | NHCH(CH ₃)CH ₂ OCH ₃ | H | F | H | H | SO ₂ Me | 0 | resin |
| A1.37 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | SO ₂ Me | 0 | resin |
| A1.38 | NHCH ₂ CH ₂ CH ₂ OH | H | H | H | Cl | Cl | 0 | solid |
| A1.39 | NHCH ₂ CH ₂ CH ₂ OH | H | H | H | Cl | H | 0 | 192-194 |
| A1.40 | NHCH ₂ CH ₂ CH ₂ OH | H | Cl | H | Cl | H | 0 | 139-142 |
| A1.41 | NHCH ₂ CH ₂ CH ₂ OH | H | H | Cl | H | Cl | 0 | 141-144 |
| A1.42 | NHCH ₂ CH ₂ CH ₂ OH | H | F | H | H | H | 0 | 123-126 |
| A1.43 | NHCH ₂ CH ₂ CH ₂ OH | H | H | H | CH ₃ | H | 0 | 185-187 |
| A1.44 | NHCH ₂ CH ₂ CH ₂ OH | H | H | H | H | SMe | 0 | 98-100 |
| A1.45 | NHCH ₂ CH ₂ CH ₂ OH | H | H | NO ₂ | H | H | 0 | 152-155 |
| A1.46 | NHC ₆ H ₃ -2F,5Cl | H | F | H | H | Cl | 0 | 234-235 |
| A1.47 | NH ₂ | H | H | H | F | Cl | 0 | solid |
| A1.48 | NHCH ₂ CH ₂ CH ₂ NHAc | H | H | H | F | Cl | 0 | solid |
| A1.49 | NHCH ₂ CH ₂ CH ₂ OH | H | H | H | OH | H | 0 | solid |
| A1.50 | NHCH ₂ CH ₂ C(=O)NH ₂ | H | H | H | F | Cl | 0 | solid |
| A1.51 | NHCH ₂ CH ₂ C(CH ₃) ₂ OH | H | H | H | F | Cl | 0 | solid |
| A1.52 | NHCH ₂ CH ₂ CH ₂ NH ₂ | H | H | H | F | Cl | 0 | solid |
| A1.53 | NHCH ₂ CH ₂ C(=O)OH | H | H | H | F | Cl | 0 | solid |
| A1.54 | NHCH ₂ CH ₂ CH ₂ OH | H | F | H | F | H | 0 | 148-151 |
| A1.55 | NHCH ₂ CH ₂ CH ₂ OH | H | Me | H | H | H | 0 | 106-109 |
| A1.56 | NHCH ₂ CH ₂ CH ₂ OH | H | Cl | H | H | H | 0 | 86-89 |
| A1.57 | NHCH ₂ CH ₂ CH ₂ OH | H | H | H | OMe | H | 0 | 142-145 |
| A1.58 | NHCH ₂ CH ₂ CH ₂ OH | H | H | H | F | H | 0 | 190-193 |
| A1.59 | NHCH ₂ CH ₂ CH ₂ OH | H | H | H | F | F | 0 | 181-184 |
| A1.60 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | CO ₂ Me | H | 0 | 1.07 min |

| | | | | | | | | |
|-------|--|---|---|-----------------|-----------------|-----------------|---|----------|
| A1.61 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | i-Prop | H | 0 | 1.5 min |
| A1.62 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | OE _t | H | 0 | 1.11 min |
| A1.63 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | F | NO ₂ | 0 | 1.15 min |
| A1.64 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | Cl | H | Cl | 0 | 1.61 min |
| A1.65 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | CF ₃ | H | CF ₃ | 0 | 1.76 min |
| A1.66 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Me | H | 0 | 1.17 min |
| A1.67 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | NH ₂ | 0 | 0.26 min |
| A1.68 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | OMe | H | 0 | 0.9 min |
| A1.69 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Br | H | 0 | 1.69 min |
| A1.70 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | NO ₂ | H | 0 | 1.15 min |
| A1.71 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Et | H | 0 | 1.3 min |
| A1.72 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | CN | H | 0 | 1.0 min |
| A1.73 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | Cl | OH | Cl | 0 | 1.02 min |
| A1.74 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | NH ₂ | H | 0 | 0.26 min |
| A1.75 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | Cl | Me | H | 0 | 1.46 min |
| A1.76 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Cl | Cl | 0 | 1.54 min |
| A1.77 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Me | NO ₂ | 0 | 1.26 min |
| A1.78 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | OMe | Cl | 0 | 1.2 min |
| A1.79 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | F | Cl | 0 | 1.35 min |
| A1.80 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | t-Bu | H | 0 | 1.65 min |
| A1.81 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | F | H | F | 0 | 1.3 min |
| A1.82 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | C(O)Et | H | 0 | 1.11 min |
| A1.83 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | N(Me) Ac | H | 0 | 0.7 min |
| A1.84 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | OMe | H | OMe | 0 | 1.11 min |
| A1.85 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | NO ₂ | 0 | 1.11 min |
| A1.86 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | SCN | H | 0 | 1.2 min |
| A1.87 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | OMe | OMe | 0 | 0.8min |
| A1.88 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Br | CF ₃ | 0 | 1.63 min |

| | | | | | | | | |
|--------|--|---|---|-----|---|--------------------|---|----------|
| A1.89 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | Br | OH | Br | 0 | 1.11 min |
| A1.90 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | OH | 0 | 0.65 min |
| A1.91 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | O-CH ₂ -O-CH ₂ | | 0 | 0.9 min |
| A1.92 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Cl | CF ₃ | 0 | 1.61 min |
| A1.93 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | OMe | CF ₃ | 0 | 1.33 min |
| A1.94 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | OH | OMe | 0 | 0.6 min |
| A1.95 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Cl | SH | 0 | 0.8 min |
| A1.96 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Cl | OH | 0 | 0.96 min |
| A1.97 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | C(O)N(Me)O Me | Cl | 0 | 0.9 min |
| A1.98 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Me | F | 0 | 1.3 min |
| A1.99 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Br | Cl | 0 | 1.56 min |
| A1.100 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | SCF ₃ | Cl | 0 | 1.82 min |
| A1.101 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | C(Me) ₂ C(Me) ₂ NO ₂ | H | 0 | 1.54 min |
| A1.102 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | SCF ₃ | H | 0 | 1.65 min |
| A1.103 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | OMe | F | 0 | 1.04 min |
| A1.104 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | OMe | H | CF ₃ | 0 | 1.48 min |
| A1.105 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | C(O)N(Et) 2 | 0 | 0.96 min |
| A1.106 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | F | CF ₃ | 0 | 1.43 min |
| A1.107 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | SO ₂ N- iProp | H | 0 | 1.0 min |
| A1.108 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | SO ₂ NE t | H | 0 | 0.9 min |
| A1.109 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | CO ₂ Me | Br | 0 | 1.26 min |
| A1.110 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | Cl | CO ₂ Me | 0 | 1.26 min |
| A1.111 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | O-CH ₂ -O | | 0 | 1.0 min |

| | | | | | | | | |
|--------|--|---|---|---|---|-----------------------------------|---|----------|
| A1.112 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | CH ₂ CO ₂ H | 0 | 0.7 min |
| A1.113 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | =N-S-N= | | 0 | 1.02 min |
| A1.114 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | SO ₂ CF ₃ | 0 | 1.41 min |
| A1.115 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | F | H | 0 | 151-152 |
| A1.116 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | C(O)-N(Me)-C(O)- | | 0 | 204-205 |
| A1.117 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | CH ₂ CN | H | 0 | 139-140 |
| A1.118 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | -O-C(O)-CH=CH- | | 0 | 170-172 |
| A1.119 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | -N(Ac)-CH ₂ -CH ₂ - | | 0 | 0.6 min |
| A1.120 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | CN | CN | 0 | 1.1 min |
| A1.121 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | N(Et) ₂ | H | 0 | 0.5 min |
| A1.122 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | NO ₂ | CF ₃ | 0 | 1.46 min |
| A1.123 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | CN | Cl | 0 | 1.26 min |
| A1.124 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | CO ₂ H | H | 0 | 0.65 min |
| A1.125 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | OMe | OH | 0 | 0.7 min |
| A1.126 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | -S-C(O)-N- | | 0 | 0.9 min |
| A1.127 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | SO ₂ CF ₃ | H | 0 | 1.48 min |
| A1.128 | NHCH(CH ₃)CH ₂ OCH ₃ | H | H | H | H | CN | 0 | 120-122 |








Further compounds of general structure I are those where A and A' are both N and the values of R₃ to R₆ corresponds with a line of Table B and the values of j, R₁ and R₂ correspond with a line of Table C.




5

Table B:





| No. | R3 | R4 | R5 | R6 |
|------|----|----|----|-------------------------------|
| B.01 | H | H | H | CH ₃ |
| B.02 | H | H | H | C ₂ H ₅ |




| | | | | |
|------|---|---|---|--------------------------------------|
| B.03 | H | H | H | t-Butyl |
| B.04 | H | H | H | iso-Propyl |
| B.05 | H | H | H | OMe |
| B.06 | H | H | H | OEt |
| B.07 | H | H | H | OCH ₂ -C≡CH |
| B.08 | H | H | H | OCH ₂ -CH=CH ₂ |
| B.09 | H | H | H | OCF ₃ |
| B.10 | H | H | H | OC(=O)NMe ₂ |
| B.11 | H | H | H | OH |
| B.12 | H | H | H | OCF ₂ CF ₃ |
| B.13 | H | H | H | F |
| B.14 | H | H | H | CL |
| B.15 | H | H | H | BR |
| B.16 | H | H | H | NO ₂ |
| B.17 | H | H | H | CN |
| B.18 | H | H | H | C(=O)OMe |
| B.19 | H | H | H | C(=O)OCH ₂ Ph |
| B.20 | H | H | H | C(=O) C ₂ H ₅ |
| B.21 | H | H | H | C(=O)NEt ₂ |
| B.22 | H | H | H | C(=O)NHCH ₂ -C≡CH |
| B.23 | H | H | H | NHSO ₂ CH ₃ |
| B.24 | H | H | H | NHSO ₂ Ph |
| B.25 | H | H | H | NHBu |
| B.26 | H | H | H | N(Et) ₂ |
| B.27 | H | H | H | NMe-nProp |







| | | | | |
|------|---|---|---|---|
| B.28 | H | H | H | NHCH ₂ -C≡CH |
| B.29 | H | H | H |  |
| B.30 | H | H | H |  |
| B.31 | H | H | H |  |
| B.32 | H | H | H |  |
| B.33 | H | H | H |  |
| B.34 | H | H | H | C(H)=NOBu |
| B.35 | H | H | H | O(CH ₂) ₂ O(CH ₂) ₂ OH |
| B.36 | H | H | H | SH |
| B.37 | H | H | H | SBu |
| B.38 | H | H | H | SMe |
| B.39 | H | H | H |  |
| B.40 | H | H | H | (CH ₂) ₂ C(=O)NHEt |
| B.41 | H | H | H | SO ₂ NHMe |
| B.42 | H | H | H | SO ₂ NMeEt |
| B.43 | H | H | H | SO ₂ NH-iProp |
| B.44 | H | H | H | SO ₂ NHEt |
| B.45 | H | H | H | SO ₂ NHBz |
| B.46 | H | H | H | SO ₂ CH ₃ |
| B.47 | H | H | H |  |



| | | | | |
|------|---|---|----------------------------|---|
| B.48 | H | H | H | $\text{CH}_2\text{-C}\equiv\text{C-Ph}$ |
| B.49 | H | H | H | $\text{O-CH}_2\text{-C}\equiv\text{C-CH}_2\text{-OH}$ |
| B.50 | H | H | H | OH |
| B.51 | H | H | H | CH_2CN |
| B.52 | H | H | H | CH_2OH |
| B.53 | H | H | H | NH_2 |
| B.54 | H | H | H | SO_2CF_3 |
| B.55 | H | H | H | SCF_3 |
| B.56 | H | H | H | $\text{C}(\text{CH}_3)_2\text{OH}$ |
| B.57 | H | H | H | -N(Me)-C(=O)Me |
| B.58 | H | H | H | -NHC(=O)Me |
| B.59 | H | H | H | S(O)Me |
| B.60 | H | H | H | $\text{CH}_2\text{-CO}_2\text{H}$ |
| B.61 | H | H | H | C(=O)Me |
| B.62 | H | H | H | $\text{-CO}_2\text{H}$ |
| B.63 | H | H | H |  |
| B.64 | H | H | H |  |
| B.65 | H | H | H | $\text{-C}\equiv\text{C-C}(\text{CH}_3)_2\text{-OH}$ |
| B.66 | H | H | H |  |
| B.67 | H | H | $\text{-O-CF}_2\text{-O-}$ | |
| B.68 | H | H | -CH=CH-NH- | |
| B.69 | H | H | -CH=CH-C(=O)-O- | |



| | | | | |
|------|---|---|---|------------------|
| B.70 | H | H | -C(=O)-N(Me)-C(=O)- | |
| B.71 | H | H | -CH ₂ -O-CH ₂ -O- | |
| B.72 | H | H | -CH=N-NH- | |
| B.73 | H | H | -O-CH ₂ -O- | |
| B.74 | H | H | -NH-N=CH- | |
| B.75 | H | H | -NH-CH=CH- | |
| B.76 | H | H | =N-S-N= | |
| B.77 | H | H | -CH=CH-SO ₂ - | |
| B.78 | H | H | -NH-CH=C(Me)- | |
| B.79 | H | H | -N(Ac)-CH ₂ -CH ₂ - | |
| B.80 | H | H | -S-C(=O)-NH- | |
| B.81 | H | H | -O-C(=O)-CH=CH- | |
| B.82 | H | H | Cl | Cl |
| B.83 | H | H | Cl | OMe |
| B.84 | H | H | Cl | Me |
| B.85 | H | H | Cl | F |
| B.86 | H | H | Cl | Br |
| B.87 | H | H | Cl | -C(=O)-N(Me)-OMe |
| B.88 | H | H | Cl | OH |
| B.89 | H | H | Cl | SCF ₃ |
| B.90 | H | H | Cl | CN |
| B.91 | H | H | CN | CN |
| B.92 | H | H | NO ₂ | Me |
| B.93 | H | H | NO ₂ | F |
| B.94 | H | H | F | OMe |

| | | | | |
|-------|---|---|---|--------------------|
| B.95 | H | H | F | Me |
| B.96 | H | H | F | F |
| B.97 | H | H | CF ₃ | OMe |
| B.98 | H | H | CF ₃ | Br |
| B.99 | H | H | CF ₃ | Cl |
| B.100 | H | H | CF ₃ | F |
| B.101 | H | H | CF ₃ | NO ₂ |
| B.102 | H | H | OMe | OMe |
| B.103 | H | H | OMe | OH |
| B.104 | H | H | OH | Cl |
| B.105 | H | H | CO ₂ Me | Cl |
| B.106 | H | H | Br | CO ₂ Me |
| B.107 | H | H | SH | Cl |
| B.108 | H | H | OH | OMe |
| B.109 | H | H |  | Cl |
| B.110 | H | H |  | Cl |
| B.111 | H | H | C(H)=NOBu | Cl |
| B.112 | H | H | (CH ₂) ₂ C(=O)NHEt | Cl |
| B.113 | H | H | C(CH ₃)=NOBu | Cl |
| B.114 | H | H |  | Cl |
| B.115 | H | H | O(CH ₂) ₂ O(CH ₂) ₂ OH | Cl |
| B.116 | H | H |  | Cl |

| | | | | |
|-------|---|---|--------------------------------------|---|
| B.117 | H | H | Cl |  |
| B.118 | H | H | Cl |  |
| B.119 | H | H | Cl |  |
| B.120 | H | H | CH ₃ | H |
| B.121 | H | H | C ₂ H ₅ | H |
| B.122 | H | H | t-Butyl | H |
| B.123 | H | H | iso-Propyl | H |
| B.124 | H | H | OMe | H |
| B.125 | H | H | OEt | H |
| B.126 | H | H | OCH ₂ -C≡CH | H |
| B.127 | H | H | OCH ₂ -CH=CH ₂ | H |
| B.128 | H | H | OCF ₃ | H |
| B.129 | H | H | OC(=O)NMe ₂ | H |
| B.130 | H | H | OH | H |
| B.131 | H | H | OCF ₂ CF ₃ | H |
| B.132 | H | H | F | H |
| B.133 | H | H | CL | H |
| B.134 | H | H | BR | H |
| B.135 | H | H | NO ₂ | H |
| B.136 | H | H | CN | H |
| B.137 | H | H | C(=O)OMe | H |
| B.138 | H | H | C(=O)OCH ₂ Ph | H |




| | | | | |
|-------|---|---|---|---|
| B.139 | H | H | $C(=O)C_2H_5$ | H |
| B.140 | H | H | $C(=O)NEt_2$ | H |
| B.141 | H | H | $C(=O)NHCH_2-C\equiv CH$ | H |
| B.142 | H | H | $NHSO_2CH_3$ | H |
| B.143 | H | H | $NHSO_2Ph$ | H |
| B.144 | H | H | $NHBu$ | H |
| B.145 | H | H | $N(Et)_2$ | H |
| B.146 | H | H | $NMe-nProp$ | H |
| B.147 | H | H | $NHCH_2-C\equiv CH$ | H |
| B.148 | H | H |  | H |
| B.149 | H | H |  | H |
| B.150 | H | H |  | H |
| B.151 | H | H |  | H |
| B.152 | H | H |  | H |
| B.153 | H | H | $C(H)=NOBu$ | H |
| B.154 | H | H | $O(CH_2)_2O(CH_2)_2OH$ | H |
| B.155 | H | H | SH | H |
| B.156 | H | H | SBu | H |
| B.157 | H | H | SMe | H |
| B.158 | H | H |  | H |
| B.159 | H | H | $(CH_2)_2C(=O)NHEt$ | H |

| | | | | |
|-------|---|---|---|---|
| B.160 | H | H | SO ₂ NHMe | H |
| B.161 | H | H | SO ₂ NMeEt | H |
| B.162 | H | H | SO ₂ NH-iProp | H |
| B.163 | H | H | SO ₂ NHEt | H |
| B.164 | H | H | SO ₂ NHBz | H |
| B.165 | H | H | SO ₂ CH ₃ | H |
| B.166 | H | H |  | H |
| B.167 | H | H | CH ₂ -C≡C-Ph | H |
| B.168 | H | H | O-CH ₂ -C≡C-CH ₂ -OH | H |
| B.169 | H | H | OH | H |
| B.170 | H | H | CH ₂ CN | H |
| B.171 | H | H | CH ₂ OH | H |
| B.172 | H | H | NH ₂ | H |
| B.173 | H | H | SO ₂ CF ₃ | H |
| B.174 | H | H | SCF ₃ | H |
| B.175 | H | H | C(CH ₃) ₂ OH | H |
| B.176 | H | H | -N(Me)-C(=O)Me | H |
| B.177 | H | H | -NHC(=O)Me | H |
| B.178 | H | H | S(O)Me | H |
| B.179 | H | H | CH ₂ -CO ₂ H | H |
| B.180 | H | H | C(=O)Me | H |
| B.181 | H | H | -CO ₂ H | H |
| B.182 | H | H |  | H |





| | | | | |
|-------|-----|-----|---|-------|
| B.183 | H | H |  | H |
| B.184 | H | H | $\text{-C}\equiv\text{C-C(CH}_3\text{)}_2\text{-OH}$ | H |
| B.185 | H | H |  | H |
| B.186 | H | Cl | H | Cl |
| B.187 | H | F | H | F |
| B.188 | H | OMe | H | OMe |
| B.189 | H | CF3 | H | CF3 |
| B.190 | H | Br | OH | Br |
| B.191 | H | Cl | OH | Cl |
| B.192 | F | H | H | H |
| B.193 | Me | H | H | H |
| B.194 | Cl | H | H | H |
| B.195 | OMe | H | H | H |
| B.196 | CN | H | H | H |
| B.197 | F | Cl | H | H |
| B.198 | Me | Cl | H | H |
| B.199 | OH | Cl | H | H |
| B.200 | Cl | H | Cl | H |
| B.201 | F | H | F | H |
| B.202 | F | H | H | Cl |
| B.203 | F | H | H | SO2Me |
| B.204 | OH | H | H | Cl |
| B.205 | OMe | H | H | Cl |



| | | | | |
|-------|----|---|---|----|
| B.206 | Me | H | H | Cl |
|-------|----|---|---|----|




Table C:

| No. | J | R ₁ | R ₂ |
|------|---|---|----------------|
| C.01 | 0 | $\text{N}(\text{CH}_3)\text{N}(\text{CH}_2\text{CF}_3)_2$ | H |
| C.02 | 0 | $\text{NHNHCH}_2\text{CH}_2\text{OCH}_3$ | H |
| C.03 | 0 | $\text{N}(\text{CH}_2\text{CH}_2\text{OCH}_3)\text{NHC}(\text{CH}_3)_3$ | H |
| C.04 | 0 | $\text{NHN}(\text{CH}_3)\text{CH}_2\text{OCH}_2\text{CH}_3$ | H |
| C.05 | 0 | $\text{NHNHC}(\text{O})\text{CH}_2\text{CH}_2\text{OCH}_3$ | H |
| C.06 | 0 | $\text{N}[\text{C}(\text{O})\text{CH}_2\text{CH}_2\text{OCH}_3]\text{NH}(\text{CH}_3)$ | H |
| C.07 | 0 | $\text{N}[\text{C}(\text{O})\text{CH}_3]\text{N}(\text{CH}_3)[\text{C}(\text{O})\text{CH}_3]$ | H |
| C.08 | 0 |  | H |
| C.09 | 0 |  | H |
| C.10 | 0 | $\text{NH}(\text{CH}_3)$ | H |
| C.11 | 0 | $\text{N}(\text{CH}_3)_2$ | H |
| C.12 | 0 | $\text{NH}[\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3]$ | H |
| C.13 | 0 | NHNH_2 | H |
| C.14 | 0 | NHNHCH_3 | H |
| C.15 | 0 |  | H |
| C.16 | 0 | $\text{NH}[\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{NHCH}_3]$ | H |
| C.17 | 0 | $\text{NH}[\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2]$ | H |
| C.18 | 0 | $\text{NH}[\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{N}(\text{CH}_3)_2]$ | H |
| C.19 | 0 | $\text{NCH}_3[(\text{CH}_2)_3\text{N}(\text{CH}_3)_2]$ | H |
| C.20 | 0 | $\text{NCH}_3[\text{CH}(\text{CH}_3)\text{CH}_2\text{N}(\text{CH}_3)_2]$ | H |
| C.21 | 0 | $\text{NH}[\text{CH}_2\text{CH}_2\text{OCH}_2\text{OCH}_3]$ | H |
| C.22 | 0 | $\text{NH}[\text{CH}_2\text{CH}_2\text{OCH}_2\text{OCH}_2\text{CH}_3]$ | H |
| C.23 | 0 | $\text{NH}(\text{CH}_2)_2\text{CN}$ | H |


| | | | |
|------|---|--|---|
| C.24 | 0 | $\text{N}(\text{CH}_3)(\text{CH}_2)_3\text{CN}$ | H |
| C.25 | 0 | $\text{NHCH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{CN}$ | H |
| C.26 | 0 | $\text{NH}(\text{CH}_2\text{CH}=\text{CH}_2)$ | H |
| C.27 | 0 | $\text{NH}(\text{CH}(\text{CH}_3)\text{CH}=\text{CH}_2)$ | H |
| C.28 | 0 | $\text{NH}(\text{CH}(\text{CH}_3)\text{CH}=\text{CH}_2)$ | H |
| C.29 | 0 | $\text{NH}(\text{CH}_2\text{C}\equiv\text{CCH}_3)$ | H |
| C.30 | 0 | $\text{NHCH}_2\text{CH}_2\text{NH}-\text{C}(\text{O})\text{CH}_2\text{CH}_3$ | H |
| C.31 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{NH}-\text{C}(\text{O})\text{CH}_2\text{CH}_3$ | H |
| C.32 | 0 | $\text{NHCH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{CH}_2\text{NH}-\text{C}(\text{O})\text{CH}_2\text{OCH}_3$ | H |
| C.33 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{NH}-$ $\text{C}(\text{O})\text{OCH}_2\text{CH}_3$ | H |
| C.34 | 0 | $\text{NHCH}(\text{CH}_3)\text{COOH}$ | H |
| C.35 | 0 | $\text{NHCH}_2\text{C}(\text{O})\text{N}(\text{CH}_3)_2$ | H |
| C.36 | 0 | $\text{NHCH}(\text{CH}_3)\text{C}(\text{O})\text{OCH}_2\text{CH}(\text{CH}_3)\text{OH}$ | H |
| C.37 | 0 | $\text{NHCH}(\text{CH}_3)\text{C}(\text{O})\text{NHCH}(\text{CH}_3)\text{OH}$ | H |
| C.38 | 0 | $\text{NHCH}_2\text{CH}_2\text{CH}_2\text{OH}$ | H |
| C.39 | 0 | $\text{NHCH}_2\text{CH}_2\text{CH}_2\text{OCH}_3$ | H |
| C.40 | 0 | $\text{NHCH}_2\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_3$ | H |
| C.41 | 0 | $\text{NHCH}[\text{CH}(\text{CH}_3)_2]\text{OCH}_3$ | H |
| C.42 | 0 | $\text{NHCH}(\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}_3)-\text{O}(\text{CH}_2)_2\text{CH}_3$ | H |
| C.43 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{OH}$ | H |
| C.44 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{OCH}_3$ | H |
| C.45 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{OCH}_2\text{CH}_3$ | H |
| C.46 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{O}(\text{CH}_2)_2\text{CH}_3$ | H |
| C.47 | 0 | $\text{NHCH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{OCH}_3$ | H |
| C.48 | 0 | $\text{NHCH}(\text{CH}_2\text{OH})\text{CH}_2\text{OH}$ | H |
| C.49 | 0 | $\text{NHCH}(\text{CH}_2\text{OH})\text{CH}_2\text{OCH}_3$ | H |
| C.50 | 0 | $\text{NHCH}(\text{CH}_2\text{OH})\text{CH}_2\text{OCH}_2\text{CH}_3$ | H |
| C.51 | 0 | $\text{NHCH}(\text{CH}_2\text{OH})\text{CH}_2\text{O}(\text{CH}_2)_2\text{CH}_3$ | H |
| C.52 | 0 | $\text{NHCH}(\text{CH}_2\text{OCH}_3)\text{CH}_2\text{OCH}_3$ | H |
| C.53 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{OH}$ | H |
| C.54 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{OCH}_3$ | H |

| | | | |
|------|---|--|---|
| C.55 | 0 | $\text{NHCH}(\text{CH}_2\text{OH})\text{CH}_2\text{CH}_2\text{OCH}_3$ | H |
| C.56 | 0 | $\text{NHCH}(\text{CH}_2\text{OCH}_3)\text{CH}_2\text{CH}_2\text{OH}$ | H |
| C.57 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}(\text{CH}_3)\text{OCH}_3$ | H |
| C.58 | 0 | $\text{NHCH}(\text{CH}_2\text{CH}_3)\text{CH}(\text{CH}_3)\text{O}-\text{CH}_2\text{CH}_3$ | H |
| C.59 | 0 | $\text{NHCH}(\text{CH}_2\text{OH})\text{CH}(\text{CH}_3)\text{O}-(\text{CH}_2)_2\text{CH}_3$ | H |
| C.60 | 0 | $\text{N}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{OCH}_3$ | H |
| C.61 | 0 | $\text{N}(\text{CH}_3)\text{CH}(\text{CH}_2\text{OH})\text{CH}_2\text{CH}_2\text{OH}$ | H |
| C.62 | 0 | $\text{N}(\text{CH}_2\text{OCH}_3)\text{CH}_2\text{CH}_2\text{OCH}_3$ | H |
| C.63 | 0 | $\text{N}(\text{CH}_2\text{OCH}_3)\text{CH}(\text{CH}_3)\text{CH}_2\text{OCH}_3$ | H |
| C.64 | 0 | $\text{N}(\text{CH}_2\text{OCH}_3)\text{CH}(\text{CH}_2\text{OH})\text{CH}_2\text{O}-\text{CH}_2\text{CH}_3$ | H |
| C.65 | 0 | $\text{N}(\text{CH}_2\text{OCH}_3)\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{O}-(\text{CH}_2)_2\text{CH}_3$ | H |
| C.66 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{SCH}_3$ | H |
| C.67 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{S}(\text{O})\text{CH}_2\text{CH}_3$ | H |
| C.68 | 0 |  | H |
| C.69 | 0 |  | H |
| C.70 | 0 |  | H |
| C.71 | 0 | $\text{HNCH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{N}=\text{C}(\text{NH}_2)\text{NH}_2$ | H |
| C.72 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{O}-(3\text{-pyridyl})$ | H |
| C.73 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2-(5\text{-pyrimidyl})$ | H |
| C.74 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2-(5\text{-pyrimidyl})$ | H |
| C.75 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{O}-(2\text{-thiazolyl})$ | H |
| C.76 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2-(4\text{-thiazolyl})$ | H |
| C.77 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2-(2\text{-furyl})$ | H |
| C.78 | 0 | $\text{NHCH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{CH}_2\text{O}-(1\text{-}[1,2,4\text{-triazolyl}])$ | H |
| C.79 | 0 | $\text{NHCOCH}(\text{CH}_3)\text{CH}=\text{CH}_2$ | H |
| C.80 | 0 | $\text{N}(\text{CH}_3)\text{CONHCH}_2\text{CH}_3$ | H |
| C.81 | 0 | $\text{NHCON}(\text{CH}_3)\text{CH}(\text{CH}_3)_2$ | H |
| C.82 | 0 |  | H |
| C.83 | 0 | $\text{N}=\text{CHNH}_2$ | H |


| | | | |
|-------|---|---|--------------------------------------|
| C.84 | 0 | $\text{N}=\text{CHN}(\text{CH}_3)_2$ | H |
| C.85 | 0 | $\text{N}=\text{C}(\text{CH}_3)\text{N}(\text{CH}_3)_2$ | H |
| C.86 | 0 |  | H |
| C.87 | 0 | $\text{N}=\text{C}(\text{NH}(\text{CH}_3))\text{N}(\text{CH}_3)_2$ | H |
| C.88 | 0 |  | H |
| C.89 | 0 | $\text{NHCH}_2\text{CH}_2\text{-(1,2,4-triazol-1-yl)}$ | H |
| C.90 | 0 | $\text{NHCH}_2\text{CH}_2\text{CH}_2\text{-(1-imidazolyl)}$ | H |
| C.91 | 0 | oxazolidin-2-one | H |
| C.92 | 0 | 4-methyl-oxazolidin-2-one | H |
| C.93 | 0 | 4-ethyl-oxazolidin-2-one | H |
| C.94 | 0 | 4-isopropyl-yl-oxazolidin-2-one | H |
| C.95 | 0 | 5-methyl-yl-oxazolidin-2-one | H |
| C.96 | 0 | 4,5-dimethyl-yl-oxazolidin-2-one | H |
| C.97 | 0 | 4,4-dimethyl-yl-oxazolidin-2-one | H |
| C.98 | 0 | oxazolidine-2-thione | H |
| C.99 | 0 | 4-methyl-2-yl-oxazolidine-2-thione | H |
| C.100 | 0 | imidazolidin-2-one | H |
| C.101 | 0 | 5-methyl-imidazolidin-2-one | H |
| C.102 | 0 | 2-oxo-2 λ^4 -[1,2,3]oxathiazolidin | H |
| C.103 | 0 | 4-methyl-2-oxo-2 λ^4 -[1,2,3]oxathiazolidin | H |
| C.104 | 0 | 4-methyl-[1,3]oxazinane | H |
| C.105 | 0 | 2-methyl-4-morpholine-3,5-dione | H |
| C.106 | 0 | 3-methyl-piperidine-2,6-dione | H |
| C.107 | 0 | 4,5-dimethyl-3[1,3]oxazinan-2-one | H |
| C.108 | 0 | 4-morpholine-3,5-dione | H |
| C.109 | 0 | (4-methyl-2-oxo-oxazolidin-5-yl)-acetonitrile | H |
| C.110 | 0 | [1,3]oxazinane-2-one | H |
| C.111 | 0 | [1,3]oxazinane-2-one | $\text{CH}_2\text{OCH}_2\text{CH}_3$ |
| C.112 | 0 | 4-methyl-[1,3]oxazinan-2-one | $\text{CH}_2\text{OCH}_2\text{CH}_3$ |

| | | | |
|-------|---|--|--|
| C.113 | 0 | 3-methyl-piperidine-2,6-dione | $\text{CH}_2\text{OCH}_2\text{CH}_3$ |
| C.114 | 0 | 5-methyl-imidazolidin-2-one | $\text{CH}_2\text{OCH}_2\text{CH}_3$ |
| C.115 | 0 | 4-methyl-oxazolidin-2-one | $\text{CH}_2\text{OCH}_2\text{CH}_3$ |
| C.116 | 0 | $\text{N}=\text{C}(\text{CH}_3)\text{N}(\text{CH}_3)_2$ | $\text{CH}_2\text{OCH}_2\text{CH}_3$ |
| C.117 | 1 |  | H |
| C.118 | 1 | $\text{NHCH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{CH}_2\text{O}-(1-[1,2,4\text{-triazolyl}])$ | H |
| C.119 | 1 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{OCH}_3$ | H |
| C.120 | 1 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{OCH}_3$ | H |
| C.121 | 1 | $\text{NHCH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{CN}$ | H |
| C.122 | 0 | $\text{N}[\text{C}(\text{O})\text{CH}_2\text{CH}_2\text{OCH}_3]\text{NH}(\text{CH}_3)$ | $\text{CH}_2\text{OCH}_2\text{CH}_3$ |
| C.123 | 0 | [1,3]oxazinane-2-one | $\text{CH}_2\text{SCH}_2\text{CH}_3$ |
| C.124 | 0 | 4-methyl-[1,3]oxazinan-2-one | $\text{CH}_2\text{SCH}_2\text{CH}_3$ |
| C.125 | 0 | 3-methyl-piperidine-2,6-dione | $\text{CH}_2\text{SCH}_2\text{CH}_3$ |
| C.126 | 0 | 5-methyl-imidazolidin-2-one | $\text{CH}_2\text{SCH}_2\text{CH}_3$ |
| C.127 | 0 | $\text{N}[\text{C}(\text{O})\text{CH}_2\text{CH}_2\text{OCH}_3]\text{NH}(\text{CH}_3)$ | $\text{CH}_2\text{CH}=\text{CH}_2$ |
| C.128 | 0 | $\text{NHCH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{CN}$ | $\text{CH}_2\text{CH}=\text{CH}_2$ |
| C.129 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{OCH}_3$ | $\text{CH}_2\text{CH}=\text{CH}_2$ |
| C.130 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{OCH}_3$ | $\text{CH}_2\text{CH}=\text{CH}_2$ |
| C.131 | 0 | $\text{NHCH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{CH}_2\text{O}-(1-[1,2,4\text{-triazolyl}])$ | $\text{CH}_2\text{CH}=\text{CH}_2$ |
| C.132 | 0 |  | $\text{CH}_2\text{OCH}_2\text{CH}_3$ |
| C.133 | 0 | $\text{N}=\text{C}(\text{CH}_3)\text{N}(\text{CH}_3)_2$ | $\text{CH}_2\text{CH}=\text{CH}_2$ |
| C.134 | 0 | 4-methyl-oxazolidin-2-one | $\text{C}(=\text{O})\text{CH}_2\text{CH}_2\text{CH}_3$ |
| C.135 | 0 | 3-methyl-piperidine-2,6-dione | SO_2CH_3 |
| C.136 | 0 |  | $\text{CH}_2\text{SCH}_2\text{CH}_3$ |
| C.137 | 0 | $\text{NHCH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{CN}$ | $\text{CH}_2(\text{OCH}_2\text{CH}_2)\text{OCH}_3$ |
| C.138 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{OCH}_3$ | $\text{CH}_2\text{OCH}_2\text{Ph}$ |
| C.139 | 0 | 4-methyl-oxazolidin-2-one | $\text{CH}_2\text{OCH}_2\text{Ph}$ |
| C.140 | 0 | [1,3]oxazinane-2-one | $\text{C}(=\text{O})\text{CH}_2\text{OCH}_3$ |
| C.141 | 0 | 4-methyl-[1,3]oxazinan-2-one | $\text{C}(=\text{O})\text{CH}(\text{CH}_3)_2$ |


| | | | |
|-------|---|--|--|
| C.142 | 0 | $\text{N}=\text{C}(\text{CH}_3)\text{N}(\text{CH}_3)_2$ | $\text{CH}_2\text{OCH}_2\text{Ph}$ |
| C.143 | 0 | $\text{NHCH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{OCH}_3$ | $\text{C}(=\text{O})\text{CH}_2\text{OCH}_3$ |
| C.144 | 0 | 5-methyl-imidazolidin-2-one | SO_2CF_3 |
| C.145 | 0 | $\text{NHCH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{CH}_2\text{O}-(1-[1,2,4\text{-triazolyl]})$ | $\text{CH}_2\text{C}\equiv\text{CH}_3$ |
| C.146 | 0 | $\text{N}[\text{C}(\text{O})\text{CH}_2\text{CH}_2\text{OCH}_3]\text{NH}(\text{CH}_3)$ | $\text{CH}_2\text{C}\equiv\text{CH}_3$ |




oxazolidin-2-one




4-methyl-oxazolidin-2-one




4-ethyl-oxazolidin-2-one




4-isopropyl-yl-oxazolidin-2-one




5-methyl-yl-oxazolidin-2-one




4,5-dimethyl-yl-oxazolidin-2-one




4,4-dimethyl-yl-oxazolidin-2-one




oxazolidine-2-thione




4-methyl-2-yl-oxazolidine-2-thione




imidazolidin-2-one




5-methyl-imidazolidin-2-one




2-oxo-2lambda*4*-[1,2,3]oxathiazolidin




4-methyl-2-oxo-2lambda*4*-[1,2,3]oxathiazolidin




4-methyl-[1,3]oxazinane




4-methyl-[1,3]oxazinan-2-one




2-methyl-4-morpholine-3,5-dione




3-methyl-piperidine-2,6-dione



4,5-dimethyl-3[1,3]oxazinan-2-one



4-morpholine-3,5-dione



(4-methyl-2-oxo-oxazolidin-5-yl)-acetonitrile

Further compounds of general structure I are those where A and A' are both CH and the values of R₃ to R₆ corresponds with a line of Table B and the values of j, R₁ and R₂ correspond with a line of Table C.

Further compounds of general structure I are those where A is CH and A' is N
5 and the values of R₃ to R₆ corresponds with a line of Table B and the values of j, R₁ and R₂ correspond with a line of Table C.

The compounds according to the invention may be prepared according to known methods. The procedures for the preparation of compounds of formula I where A is CH and A' is N are detailed in WO 01/93682 and WO 02/053560. These procedures may be
10 modified for compounds where A and A' are both N according to the procedures described in WO-0125220 A1 and in Libermann et al, Bull. Soc. Chim. Fr.; 1958, 687 and in the Examples. For compounds where A and A' are both CH the procedures are illustrated in the Examples.

The invention also relates to compositions which comprise the compounds of the
15 formula I, or a salt thereof, as an active component, in particular plant-protecting compositions, and also to their use in the agricultural sector or related areas.

Active compounds of the formula I are customarily used in the form of compositions and may be added, simultaneously or successively, to the surface or plant to be treated together with additional active compounds. These additional active
20 compounds may be either fertilizers, trace element-supplying agents or other preparations which influence plant growth. It is also possible, in this context, to use selective herbicides, such as insecticides, fungicides, bactericides, nematocides or molluscicides, or mixtures of several of these preparations, additionally, where appropriate, together with excipients, surfactants or other administration-promoting additives which are customary
25 in formulation technology (designated collectively as carrier materials herein).

Suitable excipients and additives may be solid or liquid and are those substances which are appropriate in formulation technology, for example natural or regenerated minerals, solvents, dispersants, wetting agents, adhesives, thickening agents, binding agents or fertilizers.

30 A preferred method for applying a compound of formula I, or an agrochemical composition which comprises at least one of these compounds, is administration to the leaves (foliar application). The frequency and rate of administration depend upon the risk of infestation by the corresponding pathogen. The compounds of formula I can, however,

also penetrate the plant through the roots via the soil (systemic action). If the locus of the plant is impregnated with a liquid formulation or if the substances are introduced in solid form into the soil, e.g. in the form of granules (soil application). In paddy rice crops, such granules can be applied in metered amounts to the flooded rice fields. In order to treat seeds, the compounds of formula I can, however, also be applied to the seeds (coating), either by impregnating the grains or tubers with a liquid formulation of the active ingredient, or by coating them with a solid formulation.

Advantageous rates of application are in normally from 5 g to 2 kg of active ingredient (a.i.) per hectare (ha), preferably from 10 g to 1 kg of a.i./ha, especially from 20 g to 600 g a.i./ha. When the compound are used as seed dressings, dosages of from 10 mg to 1 g of active ingredient per kg seed are advantageous employed. The agrochemical compositions generally comprise 0.1 to 99% by weight, preferably 0.1 to 95% by weight, of a compound of formula I, 99.9 to 1% by weight, preferably 99.8 to 5% by weight, of a solid or liquid adjuvant and 0 to 25% by weight, preferably 0.1 to 25 % by weight, of a surfactant. Whereas commercial products will preferably be formulated as concentrates, the end user will normally employ dilute formulations.

The compositions may also comprise further auxiliaries, such as fertilizers and other active ingredients for obtaining special desirable biological effects.

The compounds of formula I may be used preventatively and/or curatively in the sector of agronomics and related technical areas as active ingredients for controlling plant pests. The active ingredients of formula I according to the invention are notable for their good activity even at low concentrations, for their good plant tolerance and for their environmentally friendly nature. They have very advantageous, especially systemic, properties and may be used to protect a plurality of cultivated plants. Using the active ingredients of formula I on plants or plant parts (fruit, flowers, leaves, stems, tubers, roots) of various crops, the pests appearing can be controlled or destroyed, whereby the parts of plants which grow later also remain protected, e.g. from phytopathogenic microorganisms.

The compounds I may additionally be used as a dressing to treat seeds (fruits, tubers, corms) and plant cuttings to protect against fungal infections and against phytopathogenic fungi occurring in the soil.

The compounds I are effective for example against the following classes of related phytopathogenic fungi: *Fungi imperfecti* (e.g. *Botrytis*, *Pyricularia*, *Helminthosporium*,

Fusarium, Septoria, Cercospora and *Alternaria*); *Basidiomycetes* (e.g. *Rhizoctonia, Hemileia, Puccinia*); *Ascomycetes* (e.g. *Venturia* and *Erysiphe, Podosphaera, Monilinia, Uncinula*) and *Oomycetes* (e.g. *Phytophthora, Pythium, Plasmopara*).

Target crops for the plant-protecting usage in terms of the invention are for example the following plant cultivars: cereals (wheat, barley, rye, oats, rice, maize, sorghum and related species); beet (sugar beet and fodder beet); pome, stone and berry fruit (apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries and blackberries); legumes (beans, lentils, peas, soya); oil crops (rape, mustard, poppy, olives, sunflowers, coconut, castor oil, cocoa, peanut); cucumber plants (squashes, cucumber, melons); citrus fruits (oranges, lemons, grapefruits, mandarines); vegetables (spinach, lettuce, asparagus, cabbage varieties, carrots, onions, tomatoes, potatoes, paprika); laurels (avocado, cinnamomum, camphor) and plants such as tobacco, nuts, coffee, aubergines, sugar cane, tea, pepper, vines, hops, bananas and natural rubber plants, as well as ornamental plants.

Further areas of application for the active ingredients according to the invention are the protection of stores and material, where the storage matter is protected against putrescence and mould.

Furthermore the fungicidal activity allows the compounds according to present invention to be employed in controlling fungi in related areas, e.g. in protection of technical materials, including wood and wood related technical products, in food storage and in hygiene management

The compounds I are used in unchanged form or preferably together with customary excipients in formulation techniques. To this end, they are conveniently processed in known manner e.g. into emulsion concentrates, coatable pastes, directly sprayable or diluable solutions, diluted emulsions, wettable powders, soluble powders, dusts or granules, e.g. by encapsulation into for example polymeric materials. As with the type of medium, the application processes, such as spraying, atomizing, dusting, scattering, coating or pouring are similarly chosen according to the desired aims and the prevailing conditions.

Suitable substrates and additives may be solid or liquid and are useful substances in formulation techniques, e.g. natural or regenerated mineral substances, dissolving aids, dispersants, wetting agents, tackifiers, thickeners or binding agents.

The compounds of formula I may be mixed with further active ingredients, e.g.

fertilizers, ingredients providing trace elements or other active ingredients used in the plant protection science, especially further fungicides. In doing so, in some cases synergistic enhancement of the biological effects may occur.

- Preferred active ingredients advantageous as additives to the compositions comprising the active ingredient of formula I are:
- Azoles, such as azaconazole, BAY 14120, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imazalil, imibenconazole, ipconazole, metconazole, myclobutanil, pefurazoate, penconazole, pyrifenox, prochloraz, propiconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triflumizole, triticonazole; pyrimidinyl carbinole, such as ancymidol, fenarimol, nuarimol; 2-amino-pyrimidines, such as bupirimate, dimethirimol, ethirimol; morpholines, such as dodemorph, fenpropidine, fenpropimorph, spiroxamine, tridemorph; anilinopyrimidines, such as cyprodinil, mepanipyrim, pyrimethanil; pyrroles, such as fenpiclonil, fludioxonil; phenylamides, such as benalaxyl, furalaxyl, metalaxyl, R-metalaxyl, ofurace, oxadixyl; benzimidazoles, such as benomyl, carbendazim, debacarb, fuberidazole, thiabendazole; dicarboximides, such as chlozolate, dichlozoline, iprodione, myclozoline, procymidone, vinclozoline; carboxamides, such as carboxin, fenfuram, flutolanil, mepronil, oxycarboxin, thifluzamide; guanidines, such as guazatine, dodine, iminoctadine; strobilurines, such as azoxystrobin, kresoxim-methyl, metominostrobin, SSF-129, trifloxystrobin, picoxystrobin, BAS 500F (proposed name pyraclostrobin), BAS 520; dithiocarbamates, such as ferbam, mancozeb, maneb, metiram, propineb, thiram, zineb, ziram; N-halomethylthiotetrahydrophthalimides, such as captafol, captan, dichlofluanid, fluoromides, folpet, tolyfluanid; Cu-compounds, such as Bordeaux mixture, copper hydroxide, copper oxychloride, copper sulfate, cuprous oxide, mancopper, oxine-copper; nitrophenol-derivatives, such as dinocap, nitrothal-isopropyl; organo-p-derivatives, such as edifenphos, iprobenphos, isoprothiolane, phosdiphen, pyrazophos, tolclofos-methyl; various others, such as acibenzolar-S-methyl, anilazine, benthiavalicarb, blasticidin-S, chinomethionate, chloroneb, chlorothalonil, cyflufenamid, cymoxanil, dichlone, diclomezine, dicloran, diethofencarb, dimethomorph, SYP-LI90 (proposed name: flumorph), dithianon, ethaboxam, etridiazole, famoxadone, fenamidone, fenoxanil, fentin, ferimzone, fluazinam, flusulfamide, fenhexamid, fosetyl-aluminium, hymexazol, iprovalicarb, IKF-916 (cyazofamid), kasugamycin, methasulfocarb,

metrafenone, nicobifen, pencycuron, phthalide, polyoxins, probenazole, propamocarb, pyroquilon, quinoxifen, quintozone, sulfur, triazoxide, tricyclazole, triforine, validamycin, zoxamide (RH7281).

One preferred method of application of an active ingredient of formula I or of an agrochemical composition containing at least one of these active ingredients is foliar application. The frequency and amount of application depend on the severity of the attack by the pathogen in question. However, the active ingredients I may also reach the plants through the root system via the soil (systemic action) by drenching the locus of the plant with a liquid preparation or by incorporating the substances into the soil in solid form, e.g. in the form of granules (soil application). In rice cultivations, these granules may be dispensed over the flooded paddy field. The compounds I may however also be applied to seed grain to treat seed material (coating), whereby the grains or tubers are either drenched in a liquid preparation of the active ingredient or coated with a solid preparation.

The compositions are produced in known manner, e.g. by intimately mixing and/or grinding the active ingredient with extenders such as solvents, solid carriers and optionally surfactants.

Favourable application rates are in general 1 g to 2 kg of active substance (AS) per hectare (ha), preferably 10 g to 1 kg AS/ha, especially 20 g to 600 g AS/ha. For usage as a seed dressing, it is advantageous to use dosages of 10 mg to 1 g active substance per kg of seed grain.

While concentrated compositions are preferred for commercial usage, the end user normally uses diluted compositions.

Formulations may be prepared analogously to those described for example in WO 97/33890.

The invention is illustrated by the following Examples:

EXAMPLE 1

Step a. Synthesis of 2,2'-Dichloro-[4,4']-bipyridinyl.

Phosphorus oxychloride (100ml) was heated to 70 °C and pyridine (7.1ml), PCl₅ (8.1g) and [4,4']bipyridinyl 1,1'-dioxide (6.4g) were added portion wise over 30min. The mixture was then heated to reflux for 48 hours, cooled. The cooled mixture was poured drop wise onto ice with vigorous stirring, then still with ice cooling brought to pH 12-14 by adding 10M NaOH. Mixture was extracted with ethyl acetate, dried over Na₂SO₄ and

concentrated under reduced pressure. The residue was purified by passing the crude mixture down Kieselgel using 5:95 THF:CH₂Cl₂ as the eluent.

Melting point: 239-240 °C.

Step b. Synthesis of (2'-Chloro-[4,4']bipyridinyl-2-yl)-(2-methoxy-1-methyl-ethyl)-amine.

Xantphos (32mg), and Pd₂(dba)₃ (25mg) were suspended in toluene (8ml) and stirred under argon for 10mins, then 2,2'-dichloro-[4,4']-bipyridinyl (250mg), 2-amino-1-methoxypropane (0.117ml) and sodium tert-butoxide (150mg) were added. The mixture stirred at 60°C for 6hours then cooled to room temp, poured onto water and extracted with ethyl acetate, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by passing the crude mixture down Kieselgel using a gradient of hexane and ethyl acetate as the eluent.

NMR in CDCl₃, 1.3ppm,d,3H; 3.4ppm,s,3H; 3.5ppm,m,2H; 4.15ppm, m,1H; 5.0ppm, d,1H; 6.6ppm,s,1H; 6.75ppm,d,1H; 7.4ppm,d,1H; 7.52ppm,s,1H; 8.18ppm,d,1H;

8.5ppm,d,1H.


Step c. Synthesis of N*2'*(3-Chloro-phenyl)-N*2'*(2-methoxy-1-methyl-ethyl)-[4,4']bipyridinyl-2,2'-diamine.

Pd(OAc)₂ (8mg) and BINAP (16mg) were suspended in toluene (10ml) and stirred under argon for 10mins, then (2'-Chloro-[4,4']bipyridinyl-2-yl)-(2-methoxy-1-methyl-ethyl)-amine (90mg), 3-chloroaniline (124mg) and potassium carbonate (890mg) were added. The mixture was stirred at 110°C for 5 hours then cooled to room temp, poured onto water and extracted with ethyl acetate, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by passing the crude mixture down Kieselgel using 1:99 THF:CH₂Cl₂ as the eluent.

Melting point: 110 °C


EXAMPLE 2

Step a



To a solution/suspension of **1** (10.0 g; 72 mmol) in ethanol (100 mL) was added triethanolamine (4.0 mL; 39.8 mmol). H₂S was then passed through the solution. After a few minutes precipitation of a yellow solid was observed. The reaction was continued until TLC showed complete conversion (30 min). The reaction mixture was poured into ice-water (~300 mL), which resulted in precipitation of product. After stirring for 15 min the solid was filtered off, washed with water and dried (vacuum, P₂O₅). Yield: 12.1 g (97%).


Step b



10


To a solution of **2** (7.0 g; 40.6 mmol) in acetone (170 mL) was added iodomethane (12.6 mL; 202 mmol) and the reaction mixture was stirred in the dark for 3 days. The yellow precipitate was filtered off and washed with acetone and ether (2x) and dried. Yield: 8.57 g (67%).

15 Step c




To a solution of **3** (12.3 g; 39.1 mmol) in methanol (250 mL) was added ammonium acetate (6.2 g; 80.4 mmol) and the mixture was stirred at 70 °C (oil bath temp) overnight (20 h). The reaction mixture was evaporated to dryness, which gave a white residue. 2-Propanol (175 mL) was added and the suspension was stirred for 30 min. The product was filtered off and washed with 2-propanol and ether (3x) and dried. Yield: 5.6 g (66%).

Step d




To **4** (5.60 g; 26.0 mmol) were added sequentially water (250 mL), 2-propanol (100 mL), NaHCO_3 (8.53 g; 0.10 mol) and cyanamide (50 wt. % in water; 5.9 mL; 75.9 mmol) and the mixture was stirred at room temp overnight (20 h). The product was filtered off and washed with 2-propanol (2x) and ether (2x) and dried. Yield: 4.06 g (86%).

Step e




A solution of DMF (1.0 mL; 12.9 mmol) in CH_2Cl_2 (90 mL) was cooled in ice under N_2 and to this was added POCl_3 (1.3 mL; 13.9 mmol). The mixture was stirred at 0 °C for 30 min. To this was added portion-wise **5** (1.60 g; 8.9 mmol) in about 5 min. After complete addition stirring was continued for 5 h at room temp. The almost clear solution was diluted with CH_2Cl_2 (150 mL) and the organic layer was washed with sat. NaHCO_3 (2 x 200 mL) and water (200 mL), dried (NaSO_4) and evaporated to dryness. Yield: 1.89 g (94%) of a pale yellow solid. NMR: (D_6DMSO , ppm) 8.72 (1H), 8.6 (1H), (.11 (2H).

Step f



To a suspension of **6** (256 mg; 1.1 mmol) in 2-propanol (5 mL) was added 3-chloroaniline (192 μL ; 1.8 mmol) and the suspension was stirred at room temp overnight. The product was filtered off, washed with 2-propanol and dried. Yield: 305 mg (85%).

Step g



To a suspension of 7 (318 mg; 1.0 mmol) in dry toluene (4 mL) were added BINAP (50 mg; 0.080 mmol), Pd₂(dba)₃ (25 mg; 0.027 mmol), NaOtBu (220 mg; 2.3 mmol) and 2-amino-1-methoxypropane (316 µl; 3.0 mmol) and the mixture was degassed with argon for 5 min. The reaction mixture was heated at 90 °C under N₂ for 3 h, after which TLC analyses indicated that the reaction was complete. The reaction mixture was partitioned between ethyl acetate (25 mL) and water (25 mL), the layers were separated and the water layer was extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried (Na₂SO₄) and concentrated. The crude product was purified by column chromatography (SiO₂, first: EtOAc/Heptane, 1/1; then pure EtOAc). Yield: 266 mg (71%); mp: 158-159°C.

In the following, examples of test systems in plant protection are provided which can demonstrate the efficiency of the compounds of the formula I (designated as “active ingredient” or “test compounds”):

Biological Examples

Example B-1: Effect against *Puccinia graminis* on wheat (brownrust on wheat)

a) Residual protective activity

1 week old wheat plants cv. Arina are treated with the formulated test-compound (0.02 % active substance) in a spray chamber. Two days after application wheat plants are inoculated by spraying a spore suspension (1 x 10⁵ ureidospores/ml) on the test plants. After an incubation period of 1 day at +20°C and 95% relative atmospheric humidity (r. h.) plants are kept for 9 days at +20°C and 60% r.h. in a greenhouse. The disease incidence is assessed 10 days after inoculation.

At the indicated concentration compounds A1.03, A1.05, A1.10, A1.11, A1.20, A1.21, A1.45, A1.60, A1.66, A1.72, A1.84, A1.116, A1.118 and A.1.123; exhibited over 70% control of the fungal infection in this test.

Example B-2: Effect against *Plasmopara viticola* on grapevine (grape downy mildew)

5 week old grape seedlings cv. Gutedel are treated with the formulated test compound

(0.02 % active substance) in a spray chamber. One day after application grape plants are inoculated by spraying a sporangia suspension (4×10^4 sporangia/ml) on the lower leaf side of the test plants. After an incubation period of 6 days at +22°C and 95% r. h. in a greenhouse the disease incidence is assessed.

- 5 At the indicated concentration compounds A.1.45 and A.1.10, exhibited over 70% control of the fungal infection in this test.

Example B-3: Residual protective activity against *Venturia inaequalis* on apples (scab on apple)

- 10 4 week old apple seedlings cv. McIntosh are treated with the formulated test compound (0.02 % active substance) in a spray chamber. One day after application apple plants are inoculated by spraying a spore suspension (4×10^5 conidia/ml) on the test plants. After an incubation period of 4 days at +20°C and 95% r. h. the plants are transferred to standard greenhouse conditions at 20 and 60% r.h. where they stayed for 2 days. After another 4 day incubation period at +20°C and 95% r. h. the disease incidence is assessed.

- 15 At the indicated concentration compounds A1.03; A1.05, A1.10, A1.11, A1.12, A1.20, A1.21, A1.45, A1.60, A1.66, A1.72, A1.84, A1.116, A1.118, A.1.123, A1.23, A1.22, A1.64, A1.16 and A1.15, exhibited over 70% control of the fungal infection in this test.

Example B-4: Effect against *Erysiphe graminis* on barley (powdery mildew on barley)

a) Residual protective activity

- 20 Barley plants, cv. Regina of approximately 8 cm height were treated with the formulated test compound (0.02% active substance) in a spray chamber and dusted 2 days after inoculation with conidia of the fungus. The infected plants are placed in a greenhouse at +20°C. 6 days after infection, the fungal attack was evaluated.

- 25 At the indicated concentration compounds A1.03, A1.05, A1.10, A1.11, A1.12, A1.20, A1.21, A1.45, A1.60, A1.66, A1.72, A1.84, A1.116, A1.118, A.1.123, A1.23, A1.22, A1.64, A1.16 and A1.15, exhibited over 70% control of the fungal infection in this test.

Example B-5: Effect against *Botrytis cinerea* / tomato (botrytis on tomatoes)

- 30 4 week old tomato plants cv. Roter Gnom are treated with the formulated test compound (0.02 % active substance) in a spray chamber. Two days after application tomato plants are inoculated by spraying a spore suspension (1×10^5 conidia/ml) on the test plants. After an incubation period of 4 days at +20°C and 95% r. h. in a greenhouse the disease incidence is assessed.

At the indicated concentration compounds A1.03, A1.05, A1.10, A1.11, A1.12, A1.20, A1.21, A1.45, A1.60, A1.66, A1.72, A1.84, A1.116, A1.118, A.1.123, A1.23, A1.22, A1.64, A1.16 and A1.15, exhibited over 70% control of the fungal infection in this test.

Example B-6: Effect against *Pyricularia oryzae* / rice (rice blast)

5 3 week old rice plants cv. Sasanishiki are treated with the formulated test compound (0.02 % active substance) in a spray chamber. Two days after application rice plants are inoculated by spraying a spore suspension (1×10^5 conidia/ml) on the test plants. After an incubation period of 6 days at +25°C and 95% r. h. the disease incidence is assessed. At the indicated concentration compounds A1.03, A1.05, A1.10, A1.11, A1.12, A1.20, 10 A1.21, A1.45, A1.60, A1.66, A1.72, A1.84, A1.116, A1.118, A.1.123, A1.23, A1.22, A1.64, A1.16 and A1.15, exhibited over 70% control of the fungal infection in this test.

Example B-7: Effect against *Pyrenophora teres* (*Helminthosporium*) / barley (net blotch on barley)


1 week old barley plants cv. Regina are treated with a formulated test compound (0.02 % 15 active substance) in a spray chamber. Two days after application barley plants are inoculated by spraying a spore suspension (3×10^4 conidia/ml) on the test plants. After an incubation period of 2 days at +20°C and 95% r.h. the disease incidence is assessed. At the indicated concentration compounds A1.03, A1.05, A1.10, A1.11, A1.12, A1.20, A1.21, A1.45, A1.60, A1.66, A1.72, A1.84, A1.116, A1.118, A.1.123, A1.23, A1.22, 20 A1.64, A1.16, A1.15, A1.76, A1.87, A1.81 and A1.96 exhibited over 70% control of the fungal infection in this test.

Example B-8: Effect against *Septoria nodorum* / wheat (septoria leaf spot on wheat)

1 week old wheat plants cv. Arina are treated with a formulated test compound (0.02 % 25 active substance) in a spray chamber. One day after application wheat plants are inoculated by spraying a spore suspension (6×10^5 conidia/ml) on the test plants. After an incubation period of 1 day at +22°C and 95% r.h. plants are kept for 7 days at +22°C and 60% r.h. in a greenhouse. The disease incidence is assessed 8 days after inoculation. At the indicated concentration compounds A1.03, A1.05, A1.10, A1.11, A1.12, A1.20, 30 A1.21, A1.45, A1.60, A1.66, A1.72, A1.84, A1.116, A1.118, A.1.123, A1.23, A1.22, A1.64, A1.16, A1.15, A1.76, A1.87, A1.81 and A1.96 exhibited over 70% control of the fungal infection in this test.

CLAIMS

1. A compound of formula I



5 wherein

A and A' are both N or A and A' are both CH or A is CH and A' is N;

j is 0 or 1

R1 is

- a) hydrazino, that is unsubstituted or one- to threefold substituted by optionally substituted alkyl and/or optionally substituted acyl,
- b) cyclohexylamino, tetrahydro-4H-pyran-4-yl-amino, pyrrolidine-3-yl-amino, 2- or 3-tetrahydro-furyl-amino, all optionally substituted by amino, hydroxy, alkoxy, alkyl or alkoxyalkyl,
- c) piperazinyl that is optionally substituted by amino, amino-lower alkyl, hydroxy, alkoxy, alkyl or alkoxyalkyl,
- d) morpholinyl that is optionally substituted by amino, amino-lower alkyl, hydroxy, alkoxy, alkyl or alkoxyalkyl,
- e) amino or mono- or di-(lower alkyl)amino wherein the lower alkyl moieties are unsubstituted or substituted by one or more (preferably 1 to 3, especially 1 or 2) substituents independently selected from the group consisting of unsubstituted amino, N-mono- or N,N-di-(lower alkyl)-amino, (lower alkoxy)-lower alk-oxy, lower alkoxy-carbonylamino, hydroxy-lower alkoxy-carbonylamino, lower alkoxy-lower alkoxy-carbonylamino, morpholinyl, hydroxy-lower alkylamino, cyano, halogen, oxo, hydroximino, alkoximino, optionally substituted hydrazono, lower alkenyl, lower alkynyl, guanidyl, lower alkanoylamino, hydroxy-lower alkanoylamino, lower alkoxy-lower alkanoylamino, halo-lower alkanoylamino,

lower alkylaminocarbonylamino, hydroxy-lower alkylaminocarbonylamino, lower alkoxy-lower alkylaminocarbonylamino, amidino, di-lower-alkylamino-cyclohexyl, carboxy, lower alkoxycarbonyl, hydroxy-lower alkoxycarbonyl, lower alkoxy-lower alkoxycarbonyl, lower alkylcarbonyldioxy (= lower alkoxycarbonyloxy), hydroxy-

5 lower alkoxycarbonyloxy, lower alkoxy-lower alkoxycarbonyloxy, lower alkanoyloxy, halo-lower alkanoyloxy, hydroxy-lower alkanoyloxy, lower alkoxy-lower alkanoyloxy, carbamoyl, N-mono- or N,N-di-lower alkylcarbamoyl, N-(hydroxy-lower alkyl)carbamoyl, N-lower alkyl-N-hydroxy-lower alkyl-carbamoyl, N,N-di-(hydroxy-lower alkyl)-carbamoyl, N-hydroxy-carbamoyl, hydroxy, lower

10 alkoxy, lower alkenyloxy, lower alkynyloxy, lower haloalkoxy, lower alkylthio, lower alkylsulfoxyl, lower alkylsulfonyl, lower alkoxysilyl, 4-tetrahydro-4H-pyranyl, 3-pyrrolidinyl, 2- or 3-tetrahydrofuryl, 2- or 3-dihydrofuryl, piperazinyl, lower alkanoyl-piperazinyl (including formylpiperazinyl), optionally substituted heteroaryl and optionally substituted heteroaryloxy,

15 f) optionally substituted alkanoylamino, optionally substituted alkenoylamino, optionally substituted alkynoylamino, optionally substituted mono- or di-alkylaminocarbonylamino, optionally substituted alkoxycarbonylamino, optionally substituted mono- or di-alkylaminosulfonylamino, optionally substituted mono- or di-alkylaminosulfoxylamino,

20 g) N-(optionally substituted alkyl)-N-(optionally substituted lower alkanoyl)-amino, h) N-(optionally substituted alkyl)-N-(optionally substituted alkoxycarbonyl)-amino, i) N-(optionally substituted alkyl)-N-(N',N'-mono- or di-[optionally substituted alkyl]-aminocarbonyl)-amino,

25 j) $N=C(R_7, R_8)$ wherein R_7 is hydrogen, alkyl, amino, mono- or di-alkylamino and R_8 is amino, mono- or dialkylamino or wherein R_7 and R_8 , together with the binding carbon atom, form a saturated five- to seven-membered ring with 0, 1 or 2 ring nitrogen atoms that is optionally substituted by one or more substituents, preferably 1 to 3 substituents, especially lower alkyl,

30 k) an optionally substituted 4 to 7 membered heterocyclyl group containing one or two nitrogen, oxygen or sulfur atoms but at least one nitrogen atom through which the heterocyclyl ring is attached to the remainder of the molecule;

R_2 is hydrogen, C_1 - C_4 -alkyl, C_3 - C_4 -alkenyl, C_3 - C_4 -alkynyl, $-CH_2OR_{16}$, $-CH_2SR_{16}$, $-C(O)R_{16}$, $-C(O)OR_{16}$, SO_2R_{16} , SOR_{16} or SR_{16}

where R_{16} is C_1 - C_8 -alkyl, C_1 - C_8 -alkoxyalkyl, C_1 - C_8 haloalkyl or phenyl C_1 - C_2 -alkyl, wherein the phenyl may be substituted by up to three groups selected from halo or C_1 - C_4 -alkyl;

R_3 is hydrogen, halogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 haloalkoxy; hydroxy, mercapto, cyano or C_1 - C_4 alkoxy;

R_4 , R_5 and R_6 are independently of each other hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted acyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted acylamino, optionally substituted thioalkyl, $COOR_{17}$, $CONR_{18}R_{19}$, $S(O)_kR_{20}$, $SO_2NR_{21}R_{22}$, $NR_{23}R_{24}$, $NR_{25}SO_2R_{26}$, NO_2 , CN , $C(=O)R_{27}$, $C(=NOR_{28})R_{29}$ or R_4 and R_5 or R_5 and R_6 together form a five to six -membered saturated or unsaturated carbocyclic ring system or ring system or a five to six -membered heteroaromatic or heterocyclic ring system which is optionally substituted and contains one to three heteroatoms selected from O, N or S;

k is 0, 1 or 2 and


R_{17} , R_{18} , R_{19} , R_{20} , R_{21} , R_{22} , R_{23} , R_{24} , R_{25} , R_{26} , R_{27} , R_{28} and R_{29} are independently H or optionally substituted alkyl or optionally substituted aryl; or a salt thereof provided that when A is CH, A' is N and R_3 , R_5 and R_6 are all H then R_4 is not hydrogen, halogen, alkoxy, haloalkyl, haloalkoxy or alkyl.

2. A composition for controlling and protecting against phytopathogenic microorganisms, comprising a compound of formula I according to claim 1 as active ingredient together with a suitable carrier.
3. The use of a compound of formula I according to claim 1 in protecting plants against infestation by phytopathogenic microorganisms.
4. A method of controlling and preventing an infestation of crop plants by phytopathogenic microorganisms, which comprises the application of a compound of formula I according to claim 1 as active ingredient to the plant, to parts of plants or to the locus thereof.

5. A method according to claim 4, wherein the phytopathogenic microorganisms are fungal organisms.

ABSTRACT
ORGANIC COMPOUNDS

Fungicidal compounds of formula I :



(I)

wherein

A and A' are both N or A and A' are both CH or A is CH and A' is N;

j is 0 or 1 and the R groups are as defined in claim 1; their preparation, use and

compositions comprising the compounds.

PCT/IB2004/001075

